Sanofi (SNY) 6-K 29 Jul 21 Current report (foreign) Financial data

Cover page

Cover page	6 Months Ended
	Jun. 30, 2021
Entity Information [Line Items]
Document Type	6-K
Entity Registrant Name	SANOFI
Amendment Flag	false
Entity Central Index Key	0001121404
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020
Assets
Property, plant and equipment owned	€ 9,503	€ 9,365
Property, plant and equipment leased - right-of-use assets	1,473	1,198
Goodwill	44,979	44,364
Other intangible assets	19,466	18,421
Investments accounted for using the equity method	214	201
Other non-current assets	2,699	2,734
Non-current income tax assets	152	248
Deferred tax assets	4,240	4,212
Non-current assets	82,726	80,743
Inventories	9,261	8,352
Accounts receivable	6,802	7,491
Other current assets	3,094	2,737
Current income tax assets	623	1,208
Cash and cash equivalents	9,722	13,915
Current assets	29,502	33,703
Assets held for sale or exchange	93	83
TOTAL ASSETS	112,321	114,529
Equity and liabilities
Equity attributable to equity holders of Sanofi	63,237	63,001
Equity attributable to non-controlling interests	127	146
Total equity	63,364	63,147
Long-term debt	17,935	19,745
Non-current lease liabilities	1,242	931
Non-current liabilities related to business combinations and to non-controlling interests	247	387
Non-current provisions and other non-current liabilities	7,022	7,536
Non-current income tax liabilities	1,692	1,733
Deferred tax liabilities	1,674	1,770
Non-current liabilities	29,812	32,102
Accounts payable	5,374	5,295
Current liabilities related to business combinations and to non-controlling interests	200	218
Current provisions and other current liabilities	10,493	10,132
Current income tax liabilities	588	604
Current lease liabilities	247	232
Short-term debt and current portion of long-term debt	2,225	2,767
Current liabilities	19,127	19,248
Liabilities related to assets held for sale or exchange	18	32
TOTAL EQUITY AND LIABILITIES	€ 112,321	€ 114,529

Consolidated Income Statements

Consolidated Income Statements - EUR (€) € in Millions, shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Profit (loss) [abstract]
Net sales	€ 17,335	€ 17,180	€ 36,041
Other revenues	596	574	1,328
Cost of sales	(5,541)	(5,543)	(12,157)
Gross profit	12,390	12,211	25,212
Research and development expenses	(2,663)	(2,692)	(5,529)
Selling and general expenses	(4,530)	(4,607)	(9,390)
Other operating income	409	281	696
Other operating expenses	(709)	(693)	(1,415)
Amortization of intangible assets	(775)	(883)	(1,681)
Impairment of intangible assets	(178)	(323)	(330)
Fair value remeasurement of contingent consideration	(4)	54	124
Restructuring costs and similar items	(327)	(758)	(1,064)
Other gains and losses, and litigation	0	136	136
Gain on Regeneron investment arising from transaction of May 29, 2020	0	7,382	7,382
Operating income	3,613	10,108	14,141
Financial expenses	(189)	(198)	(390)
Financial income	28	31	53
Income before tax and investments accounted for using the equity method	3,452	9,941	13,804
Income tax expense	(682)	(994)	(1,813)
Share of profit/(loss) from investments accounted for using the equity method	26	354	359
Net income	2,796	9,301	12,350
Net income attributable to non-controlling interests	20	20	36
Net income attributable to equity holders of Sanofi	€ 2,776	€ 9,281	€ 12,314
Average number of shares outstanding (in shares)	1,250.3	1,251.7	1,253.6
Average number of shares after dilution (in shares)	1,255.6	1,258.2	1,260.1
Basic earnings per share (in euros per share)	€ 2.22	€ 7.41	€ 9.82
Diluted earnings per share (in euros per share)	€ 2.21	€ 7.38	€ 9.77

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Statement of comprehensive income [abstract]
Net income	€ 2,796	€ 9,301	€ 12,350
Attributable to equity holders of Sanofi	2,776	9,281	12,314
Attributable to non-controlling interests	20	20	36
Other comprehensive income:
Actuarial gains/(losses)	328	(146)	(268)
Change in fair value of equity instruments included in financial assets	67	299	320
Tax effects	(15)	(89)	(40)
Items not subsequently reclassifiable to profit or loss	380	64	12
Change in fair value of debt instruments included in financial assets	(17)	4	15
Change in fair value of cash flow hedges	(4)	29	4
Change in currency translation differences	1,061	(944)	(3,978)
Tax effects	34	9	(63)
Items subsequently reclassifiable to profit or loss	1,074	(902)	(4,022)
Other comprehensive income for the period, net of taxes	1,454	(838)	(4,010)
Comprehensive income	4,250	8,463	8,340
Attributable to equity holders of Sanofi	4,228	8,451	8,324
Attributable to non-controlling interests	€ 22	€ 12	€ 16

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - EUR (€) € in Millions		Total	Attributable to equity holders of Sanofi	Share capital	Additional paid-in capital	Treasury shares	Reserves and retained earnings	Stock options and other share-based payments	Other comprehensive income	Attributable to non- controlling interests
Beginning balance at Dec. 31, 2018		€ 59,035	€ 58,876	€ 2,495	€ 13	€ (153)	€ 53,093	€ 3,596	€ (168)	€ 159
Other comprehensive income for the period		650	651				(162)		813	(1)
Net income for the period		2,837	2,806				2,806			31
Comprehensive income		3,487	3,457				2,644		813	30
Dividend paid out of earnings		(3,834)	(3,834)				(3,834)
Payment of dividends to non-controlling interests		(14)								(14)
Share repurchase program	[1]	(12)	(12)			(12)
Share-based payment plans:
Exercise of stock options		147	147	6	141
Issuance of restricted shares and vesting of existing restricted shares	[2]	0		7	(7)	153	(153)
Proceeds from sale of treasury shares on exercise of stock options		3	3			3
Value of services obtained from employees		252	252					252
Tax effects of the exercise of stock options		15	15					15
Other changes arising from issuance of restricted shares	[3]	30	30				30
Change in non-controlling interests without loss of control		(8)	(7)				(7)			(1)
Other	[4]	7	7				7
Ending balance at Dec. 31, 2019		59,108	58,934	2,508	147	(9)	51,780	3,863	645	174
Other comprehensive income for the period		(838)	(830)				64		(894)	(8)
Net income for the period		9,301	9,281				9,281			20
Comprehensive income		8,463	8,451				9,345		(894)	12
Dividend paid out of earnings		(3,937)	(3,937)				(3,937)
Payment of dividends to non-controlling interests		(4)								(4)
Share repurchase program	[1]	(361)	(361)			(361)
Share-based payment plans:
Exercise of stock options		38	38	1	37
Issuance of restricted shares and vesting of existing restricted shares	[2]	0		3	(3)	126	(126)
Value of services obtained from employees		165	165					165
Tax effects of the exercise of stock options		12	12					12
Other changes arising from issuance of restricted shares	[3]	2	2				2
Ending balance at Jun. 30, 2020		63,486	63,304	2,512	181	(244)	57,064	4,040	(249)	182
Beginning balance at Dec. 31, 2019		59,108	58,934	2,508	147	(9)	51,780	3,863	645	174
Other comprehensive income for the period		(4,010)
Net income for the period		12,350
Comprehensive income		8,340
Ending balance at Dec. 31, 2020		63,147	63,001	2,518	362	(705)	60,046	4,138	(3,358)	146
Beginning balance at Jun. 30, 2020		63,486	63,304	2,512	181	(244)	57,064	4,040	(249)	182
Other comprehensive income for the period		(3,172)	(3,160)				(51)		(3,109)	(12)
Net income for the period		3,049	3,033				3,033			16
Comprehensive income		(123)	(127)				2,982		(3,109)	4
Payment of dividends to non-controlling interests		(40)								(40)
Share repurchase program	[1]	(461)	(461)			(461)
Share-based payment plans:
Exercise of stock options		13	13	1	12
Value of services obtained from employees		109	109					109
Tax effects of the exercise of stock options		(11)	(11)					(11)
Employee share ownership plan		174	174	5	169
Ending balance at Dec. 31, 2020		63,147	63,001	2,518	362	(705)	60,046	4,138	(3,358)	146
Other comprehensive income for the period		1,454	1,452				380		1,072	2
Net income for the period		2,796	2,776				2,776			20
Comprehensive income		4,250	4,228				3,156		1,072	22
Dividend paid out of earnings		(4,008)	(4,008)				(4,008)
Payment of dividends to non-controlling interests		(41)								(41)
Share repurchase program	[1]	(140)	(140)			(140)
Share-based payment plans:
Exercise of stock options		4	4		4
Issuance of restricted shares and vesting of existing restricted shares	[2]	0		4	(4)	148	(148)
Value of services obtained from employees		134	134					134
Tax effects of the exercise of stock options		18	18					18
Ending balance at Jun. 30, 2021		€ 63,364	€ 63,237	€ 2,522	€ 362	€ (697)	€ 59,046	€ 4,290	€ (2,286)	€ 127
[1]	See Note B.8.2.
[2]	This line includes restricted share awards fulfilled using existing shares.
[3]	Issuance of restricted shares to former employees of the Animal Health business and the European Generics business subsequent to the date of divestment.
[4]	This line includes the impact of the settlement of a put option granted to non-controlling interests in connection with a divestment.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - € / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019
Statement of changes in equity [abstract]
Dividend paid per share (in euros per share)	€ 3.20	€ 3.15	€ 3.07

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Statement of cash flows [abstract]
Net income attributable to equity holders of Sanofi		€ 2,776	€ 9,281	€ 12,314
Net income attributable to non-controlling interests		20	20	36
Share of undistributed earnings from investments accounted for using the equity method		(8)	(327)	(339)
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets		1,726	2,013	3,684
Gains and losses on disposals of non-current assets, net of tax	[1]	(105)	(177)	(301)
Gain on Regeneron investment arising from transaction of May 29, 2020, net of tax		0	(6,870)	(6,880)
Net change in deferred taxes		(134)	(296)	(214)
Net change in non-current provisions and other non-current liabilities	[2]	(151)	317	(142)
Cost of employee benefits (stock options and other share-based payments)		134	168	274
Impact of the workdown of acquired inventories remeasured at fair value		0	36	53
Other profit or loss items with no cash effect		(39)	155	(711)
Operating cash flow before changes in working capital		4,219	4,320	7,774
(Increase)/decrease in inventories		(821)	(1,023)	(593)
(Increase)/decrease in accounts receivable		751	516	(134)
Increase/(decrease) in accounts payable		(89)	(325)	86
Net change in other current assets and other current liabilities		694	438	316
Net cash provided by/(used in) operating activities	[3]	4,754	3,926	7,449
Acquisitions of property, plant and equipment and intangible assets		(1,018)	(682)	(2,114)
Acquisitions of consolidated undertakings and investments accounted for using the equity method	[4]	(1,520)	(2,360)	(5,336)
Acquisitions of other equity investments		(71)	(17)	(137)
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[5]	299	709	918
Net proceeds from sale of Regeneron shares on May 29, 2020	[6]	0	10,512	10,370
Net change in other non-current assets		(29)	(87)	(113)
Net cash provided by/(used in) investing activities		(2,339)	8,075	3,588
Issuance of Sanofi shares		23	38	203
Dividends paid:
Dividends paid to shareholders of Sanofi		(4,008)	(3,937)	(3,937)
Dividends paid to non-controlling interests		(41)	(4)	(44)
Additional long-term debt contracted		1	2,014	2,019
Repayments of long-term debt		(2,211)	(3,954)	(3,952)
Repayment of lease liabilities		(106)	(121)	(234)
Net change in short-term debt and other financial instruments		(134)	923	282
Acquisitions of treasury shares		(140)	(361)	(822)
Net cash provided by/(used in) financing activities		(6,616)	(5,402)	(6,485)
Impact of exchange rates on cash and cash equivalents		8	(57)	(64)
Net change in cash and cash equivalents		(4,193)	6,542	4,488
Cash and cash equivalents, beginning of period		13,915	9,427	9,427
Cash and cash equivalents, end of period		€ 9,722	€ 15,969	€ 13,915
[1]	Includes non-current financial assets.
[2]	This line item includes contributions paid to pension funds (see Note B.12.).
[3]	Of which: June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) ▪ Income tax paid (220) (383) (2,051) ▪ Interest paid (180) (174) (315) ▪ Interest received 1 29 37
[4]	This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations.For the six months ended June 30, 2021, it includes the net cash outflow arising from the acquisitions of Kymab, Kiadis and Tidal (see Note B.1.).
[5]	This line item includes proceeds from disposals of investments in consolidated entities and of other non-current financial assets, net of tax (including €10 million of deferred taxes as of June 30, 2021). For the six months ended June 30, 2021, it includes the divestment of operations relating to certain established prescription products for a selling price of €84 million before taxes. For the six months ended June 30, 2020 and the year ended December 31, 2020 it includes (i) the sale of operations relating to the Seprafilm ® product to Baxter (for a selling price of €313 million before taxes as of June 30, 2020 and €311 million before taxes as of December 31, 2020); (ii) the divestment of certain established prescription products (for a selling price of €105 million before taxes as of June 30, 2020 and €97 million before taxes as of December 31, 2020); and (iii) contingent consideration of €167 million before taxes relating to a past divestment.
[6]	The net proceeds from the sale of Regeneron shares as of December 31, 2020 are presented net of taxes.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Condensed Cash Flow Statements, Captions [Line Items]
Income tax paid		€ (220)	€ (383)	€ (2,051)
Interest paid		(180)	(174)	(315)
Interest received		1	29	37
Deferred tax expense		(124)	(133)	(99)
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[1]	299	709	918
Seprafilm
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax			313	311
Pharmaceuticals
Condensed Cash Flow Statements, Captions [Line Items]
Deferred tax expense		10
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax		€ 84	105	97
Contingent consideration relating to divestments
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax			€ 167	€ 167
[1]	This line item includes proceeds from disposals of investments in consolidated entities and of other non-current financial assets, net of tax (including €10 million of deferred taxes as of June 30, 2021). For the six months ended June 30, 2021, it includes the divestment of operations relating to certain established prescription products for a selling price of €84 million before taxes. For the six months ended June 30, 2020 and the year ended December 31, 2020 it includes (i) the sale of operations relating to the Seprafilm ® product to Baxter (for a selling price of €313 million before taxes as of June 30, 2020 and €311 million before taxes as of December 31, 2020); (ii) the divestment of certain established prescription products (for a selling price of €105 million before taxes as of June 30, 2020 and €97 million before taxes as of December 31, 2020); and (iii) contingent consideration of €167 million before taxes relating to a past divestment.

Introduction

Introduction	6 Months Ended
	Jun. 30, 2021
General Information About Financial Statements [Abstract]
Introduction	INTRODUCTION Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY). The condensed consolidated financial statements for the six months ended June 30, 2021 were reviewed by the Sanofi Board of Directors at the Board meeting on July 28, 2021.

Basis of Preparation of the Hal

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	6 Months Ended
	Jun. 30, 2021
Corporate Information And Statement Of IFRS Compliance [Abstract]
Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIES A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS) The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2021 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2021 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2021 are identical to those presented in the consolidated financial statements for the year ended December 31, 2020. As a reminder, Sanofi early adopted the Phase 2 amendment to IFRS 9 relating to interest rate benchmark reform in its consolidated financial statements for the year ended December 31, 2020. A.2. USE OF ESTIMATES The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment and intangible assets; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of financial assets at amortized cost; • the amount of post-employment benefit obligations; • the amount of liabilities or provisions for restructuring, litigation, tax risks and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences. Actual results could differ from these estimates. For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. A.3. SEASONAL TRENDS Sanofi’s activities are not subject to significant seasonal fluctuations. A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES In 2021, Sanofi continues to account for subsidiaries in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. In 2018, following a change to the foreign exchange system, the “DICOM” rate was replaced by the “PETRO” rate (with a floating US dollar/bolivar parity) and the strong bolivar (“VEF”) by a new currency known as the sovereign bolivar (“VES”), reflecting a 1-for-100,000 devaluation. Consequently, the contribution of the Venezuelan subsidiaries to the Sanofi consolidated financial statements is immaterial. In Argentina and Lebanon, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in those countries. Consequently, Sanofi has treated Argentina (since July 1, 2018) and Lebanon (since January 1, 2020) as hyperinflationary economies, and applied IAS 29. The impact on the financial statements of adjustments required for the application of IAS 29 in respect of Argentina and Lebanon as of June 30, 2021 is immaterial. A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2020. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps (c) Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps (c) Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) The fair value of the Dexcom equity derivatives (see Note B.10.3) is classified as Level 2 because the valuation is based on a generally accepted technique (the Black & Scholes model) that uses inputs from directly observable market parameters (share price, risk free rate and implied volatility). A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM JULY 2021 OR LATER On February 12, 2021, the IASB issued an amendment to IAS 1 concerning accounting policy disclosures, and an amendment to IAS 8 concerning the definition of accounting estimates. On May 7, 2021, the IASB issued an amendment to IAS 12 concerning deferred tax related to assets and liabilities arising from a single transaction. Sanofi does not expect any material impact from the application of these two amendments, which are effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after January 1, 2023. Sanofi will not early adopt these amendments. On March 31, 2021, the IASB issued a second “Covid-19-Related Rent Concessions” amendment to IFRS 16, effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after July 1, 2021. The amendment enables lessees, subject to certain conditions, to opt out of the requirement to determine whether a Covid-19-related rent concession is a lease modification . Sanofi does not expect a material impact from the application of this amendment. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1. On May 14, 2020, the IASB issued “Reference to the Conceptual Framework”, an amendment to IFRS 3; “Proceeds before Intended Use”, an amendment to IAS 16; “Onerous Contracts – Cost of Fulfilling a Contract”, an amendment to IAS 37; and “Annual Improvements to IFRS standards 2018-2020”. Sanofi does not expect a material impact from those amendments, which are effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after January 1, 2022. Sanofi will not early adopt these amendments . In its April 2021 update, the IFRS IC published an agenda decision clarifying how to calculate the obligation relating to certain defined benefit plans under which the retirement benefit is (i) contingent on the employee being employed by the entity at the time of retirement and (ii) capped at a specified number of years of service. The impacts of this decision on Sanofi are under review. In its March 2021 update, the IFRS IC published an agenda decision clarifying how to account for costs of configuring or customising a supplier’s application software in a Software as a Service (SaaS) arrangement. The impacts of this decision on Sanofi are under review. A.7. COVID-19 PANDEMIC As a reminder, Covid-19 – confirmed as a pandemic by the World Health Organisation on March 11, 2020 – had no major impact on the Sanofi consolidated financial statements for the six months ended June 30, 2020 or the year ended December 31, 2020. Specifically, the pandemic did not create any uncertainties that appreciably called into question the estimates and assumptions made by management. In the first half of 2021, a return to normal activity levels was observed in the principal markets where Sanofi operates. Sanofi will continue to monitor the situation, and to update management’s estimates and assumptions accordingly. Effect of the Covid-19 pandemic on accounts receivable As of June 30, 2021, Sanofi has identified nothing that would indicate a material increase in expected credit risk, especially as regards its principal customers (see Note B.20.4). Effect of the Covid-19 pandemic on the liquidity position The Covid-19 pandemic did not have a negative impact on Sanofi’s liquidity position. A.8. AGREEMENTS RELATING TO THE RECOMBINANT COVID-19 VACCINE CANDIDATE DEVELOPED BY SANOFI IN COLLABORATION WITH GSK On May 27, 2021, Sanofi and GlaxoSmithKline (GSK) initiated an international Phase III trial to evaluate the efficacy of their COVID-19 vaccine candidate. As of June 30, 2021, that new stage in the development of the vaccine candidate has not altered the funding commitments made by the United States during 2020, or the pre-orders placed by Canada, the United Kingdom or the European Union (see Note A.7. to the consolidated financial statements for the year ended December 31, 2020). Sanofi has recognized the US government funding as a deduction from the research and development expenses incurred, or from the acquisition cost of the property, plant and equipment acquired, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance).

Main Acquisitions of the Period

Main Acquisitions of the Period	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Main Acquisitions of the Period	B.1. MAIN ACQUISITIONS OF THE PERIOD Acquisition of Kymab On April 8, 2021, Sanofi acquired the entire share capital of Kymab for an upfront payment of $1.1 billion (€973 million) and up to $350 million contingent upon reaching certain development milestones. Sanofi elected to apply the optional test to identify concentration of fair value under paragraph B7A of IFRS 3. The transaction was accounted for as an asset acquisition given that the principal asset (the KY1005 project, currently in phase II clinical development, and relating to the human monoclonal antibody OX40L, an essential regulator of the immune system) concentrates substantially all of the fair value of the acquired set of activities and assets. Of the total acquisition price paid, €956 million was allocated to Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of €922 million. Acquisition of Kiadis On November 2, 2020, Sanofi and Kiadis, a biopharmaceutical company developing novel "off-the-shelf" natural killer (NK) cell therapies for patients with life-threatening diseases, entered into a definitive agreement whereby Sanofi was to make a public offer to acquire the entire share capital of Kiadis, 61,084,776 shares, at a cash price of €5.45 per share. The acquisition was approved unanimously by the Boards of Directors of Sanofi and Kiadis, and 95.03% of the share capital of Kiadis had been tendered into the offer as of April 16, 2021. As of the end of the post-closing acceptance period on April 29, 2021, Sanofi held 97.39% of the share capital of Kiadis, and launched a statutory public buy-out procedure in order to obtain 100% of the share capital. Sanofi elected to apply the optional test to identify concentration of fair value under paragraph B7A of IFRS 3. The transaction was accounted for as an asset acquisition given that the principal asset (the K-NK technology platform) concentrates substantially all of the fair value of the acquired set of activities and assets. Of the total acquisition price paid, €333 million was allocated to Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of €319 million. Acquisition of Tidal On April 9, 2021, Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a unique mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in immuno-oncology and inflammatory diseases, and may have applicability to other disease areas as well. Tidal Therapeutics was acquired for an upfront payment of $160 million (€136 million), and up to $310 million contingent upon reaching certain development milestones. Sanofi elected to apply the optional test to identify concentration of fair value under paragraph B7A of IFRS 3. The transaction was accounted for as an asset acquisition given that the principal asset (the unique mRNA-based in vivo reprogramming technology) concentrates substantially all of the fair value of the acquired set of activities and assets. Of the total acquisition price paid, €130 million was allocated to Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of €135 million.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Property, Plant and Equipment	B.2. PROPERTY, PLANT AND EQUIPMENT B.2.1. Property, plant and equipment owned The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2021: (€ million) June 30, 2021 December 31, 2020 Acquisitions 523 1,310 Pharmaceuticals 356 831 Industrial facilities 232 634 Research sites 72 152 Other 52 45 Vaccines 140 384 Consumer Healthcare 27 95 Capitalized interest 6 11 Firm orders for property, plant and equipment stood at €764 million as of June 30, 2021. B.2.2. Property, plant and equipment leased - right-of-use assets In December 2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April 2021. Consequently, Sanofi recognized a right-of-use-asset and a lease liability in its balance sheet. As of June 30, 2021, the right-of-use asset amounted to €313 million. The second lease, relating to laboratory facilities, began on July 1, 2021. The undiscounted, non-cancellable obligation amounted to €479 million as of June 30, 2021.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2021
Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	B.3. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill amounted to €44,979 million as of June 30, 2021, versus €44,364 million as of December 31, 2020. The movement during the period was mainly due to the impact of changes in exchange rates. Movements in other intangible assets during the first half of 2021 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2021 9,600 61,074 1,748 72,422 Changes in scope of consolidation (a) 1,337 82 — 1,419 Acquisitions and other increases 277 63 74 414 Disposals and other decreases — (68) (13) (81) Currency translation differences 229 803 12 1,044 Transfers (7) 10 (5) (2) Gross value at June 30, 2021 11,436 61,964 1,816 75,216 Accumulated amortization and impairment at January 1, 2021 (3,508) (49,345) (1,148) (54,001) Amortization expense — (797) (71) (868) Impairment losses, net of reversals (b) (137) (41) — (178) Disposals and other decreases 1 37 12 50 Currency translation differences (50) (693) (10) (753) Accumulated amortization and impairment at June 30, 2021 (3,694) (50,839) (1,217) (55,750) Carrying amount at January 1, 2021 6,092 11,729 600 18,421 Carrying amount at June 30, 2021 7,742 11,125 599 19,466 (a) See Note B.1. (b) See Note B.4. Acquisitions of other intangible assets (excluding software) in the first half of 2021 totaled €340 million. The main items were upfront and milestone payments within the Specialty Care and Vaccines GBUs. “Products, trademarks and other rights” mainly comprises: • marketed products, with a carrying amount of €10.5 billion as of June 30, 2021 (versus €11.4 billion as of December 31, 2020) and a weighted average amortization period of approximately 10 years; • technological platforms brought into service, with a carrying amount of €0.4 billion as of June 30, 2021 (versus €0.2 billion as of December 31, 2020 ) and a weighted average amortization period of approximately 13 years; and

Impairment of Intangible Assets

Impairment of Intangible Assets	6 Months Ended
	Jun. 30, 2021
Impairment Of Assets [Abstract]
Impairment of Intangible Assets	B.4. IMPAIRMENT OF INTANGIBLE ASSETS The results of impairment tests on other intangible assets led to the recognition of a net impairment loss of €178 million in the first half of 2021. Most of the impairment losses recognized during the period related to research and development projects in the Pharmaceuticals and Vaccines segments.

Investments Accounted for Using

Investments Accounted for Using the Equity Method	6 Months Ended
	Jun. 30, 2021
Interests In Other Entities [Abstract]
Investments Accounted for Using the Equity Method	B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2020), and comprise: (€ million) % interest June 30, 2021 December 31, 2020 Infraserv GmbH & Co. Höchst KG (a) 31.2 69 72 MSP Vaccine Company (b) 50.0 67 44 Other investments — 78 85 Total 214 201 (a) Joint venture. (b) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine B.V. The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2021 June 30, 2020 December 31, 2020 Sales (a) 31 52 75 Royalties and other income (a) 26 65 97 Accounts receivable and other receivables 66 7 50 Purchases and other expenses (including research expenses) (a) 124 605 747 Accounts payable and other payables 17 5 15

Other Non-Current Assets

Other Non-Current Assets	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Other Non-Current Assets	B.6. OTHER NON-CURRENT ASSETS Other non-current assets comprise: (€ million) June 30, 2021 December 31, 2020 Equity instruments at fair value through other comprehensive income 669 588 Debt instruments at fair value through other comprehensive income 409 426 Other financial assets at fair value through profit or loss 836 890 Pre-funded pension obligations 179 177 Long-term prepaid expenses 77 92 Long-term loans and advances and other non-current receivables 508 537 Derivative financial instruments 21 24 Total 2,699 2,734

Accounts Receivable

Accounts Receivable	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Accounts Receivable	B.7. ACCOUNTS RECEIVABLE Accounts receivable break down as follows: (€ million) June 30, 2021 December 31, 2020 Gross value 6,932 7,633 Allowances (130) (142) Carrying amount 6,802 7,491 The impact of allowances against accounts receivable in the first half of 2021 was a net expense of €2 million (versus a net expense of €40 million for the first half of 2020). The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2021 427 78 105 96 33 115 December 31, 2020 549 271 97 52 34 95 Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2020 and hence were derecognized was €522 million as of June 30, 2021 (versus €18 million as of December 31, 2020). The residual guarantees relating to those transfers were immaterial as of June 30, 2021.

Consolidated Shareholders' Equi

Consolidated Shareholders' Equity	6 Months Ended
	Jun. 30, 2021
Share Capital, Reserves And Other Equity Interest [Abstract]
Consolidated Shareholders' Equity	B.8. CONSOLIDATED SHAREHOLDERS’ EQUITY B.8.1. SHARE CAPITAL As of June 30, 2021, the share capital was €2,521,571,560 and consisted of 1,260,785,780 shares (the total number of shares outstanding) with a par value of €2. Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2021 8.25 0.655 % December 31, 2020 8.28 0.658 % June 30, 2020 2.59 0.207 % January 1, 2020 0.02 0.002 % A total of 62,396 shares were issued in the first half of 2021 as a result of the exercise of Sanofi stock subscription options. A total of 1,751,646 shares vested under Sanofi restricted share plans during the first half of 2021, either by issuance of new shares or by vesting of existing restricted shares. B.8.2. REPURCHASE OF SANOFI SHARES On April 30, 2021, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did not use that authorization during the first half of 2021. On April 28, 2020, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program (and that program alone), Sanofi repurchased 1,758,569 of its own shares during the first half of 2021 for a total amount of €140 million. B.8.3. REDUCTIONS IN SHARE CAPITAL No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2021. B.8.4. RESTRICTED SHARE PLANS Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2020. The principal features of the plans awarded in 2021 are set forth below: 2021 Type of plan Performance share plan Date of Board meeting approving the plan April 30, 2021 Total number of shares subject to a 3-year service period 3,484,420 Of which with no market condition 2,209,901 Fair value per share awarded (€) (a) 77.27 Of which with market condition 1,274,519 Fair value per share awarded (€) (b) 71.30 Fair value of plan at the date of grant (€ million) 262 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2021 June 30, 2020 Total expense for restricted share plans (€ million) 83 113 Number of shares not yet fully vested 9,996,495 10,900,815 Under 2021 plans 3,484,420 — Under 2020 plans 3,175,084 3,340,501 Under 2019 plans 3,252,099 3,545,507 Under 2018 plans 84,892 4,014,807 B.8.5. CAPITAL INCREASES On February 4, 2021, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of €69.38 per share. The subscription period was open from June 7 through June 25, 2021. Sanofi employees subscribed for a total of 2,438,590 shares, and this capital increase was supplemented by the immediate issuance of a further 124,112 shares for the employer’s contribution. The total expense recognized for this capital increase in the first half of 2021 was €51 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees. On February 5, 2020, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of €70.67 per share. The subscription period was open from June 8 through June 26, 2020. Sanofi employees subscribed for a total of 2,467,101 shares, and this capital increase was supplemented by the immediate issuance of a further 123,615 shares for the employer’s contribution. The total expense recognized for this capital increase in the first half of 2020 was €52 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees. B.8.6. STOCK SUBSCRIPTION OPTION PLANS No stock subscription option plans were awarded in the first half of 2021 or 2020. The expense recognized through equity for stock option plans is immaterial. The table below provides summary information about options outstanding and exercisable as of June 30, 2021: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €50.00 to €60.00 per share 163,367 0.68 56.44 163,367 56.44 From €60.00 to €70.00 per share 168,784 6.85 65.84 — — From €70.00 to €80.00 per share 1,499,313 3.60 74.10 1,279,313 73.65 From €80.00 to €90.00 per share 634,184 4.86 89.19 634,184 89.19 Total 2,465,648 2,076,864 B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Average number of shares outstanding 1,250.3 1,251.7 1,253.6 Adjustment for stock options with dilutive effect 0.3 0.4 0.4 Adjustment for restricted shares 5.0 6.1 6.1 Average number of shares used to compute diluted earnings per share 1,255.6 1,258.2 1,260.1 As of June 30, 2021, 0.6 million stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect, compared with 0.6 million as of December 31, 2020 and 0.7 million as of June 30, 2020. B.8.8. OTHER COMPREHENSIVE INCOME Movements within other comprehensive income are shown below: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method 328 (146) (267) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — — (1) ▪ Tax effects (11) (19) 45 Equity instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) 70 365 358 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — (13) (14) ▪ Equity risk hedging instruments designated as fair value hedges (3) (53) (24) ▪ Tax effects (4) (70) (85) Items not subsequently reclassifiable to profit or loss 380 64 12 Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) (17) 4 15 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects 4 (1) (3) Cash flow hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) (4) 29 4 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects — (9) (2) Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) 1,171 (590) (3,872) ▪ Currency translation differences (investments accounted for using the equity method) (b) (3) 24 32 ▪ Currency translation differences related to the investment in Regeneron and reclassified to profit or loss (c) — (318) (318) ▪ Hedges of net investments in foreign operations (b) (107) (60) 180 ▪ Tax effects 30 19 (58) Items subsequently reclassifiable to profit or loss 1,074 (902) (4,022) (a) Includes reclassifications to profit or loss: €4 million in the first half of 2021, and €5 million in 2020. (b) Includes reclassifications to profit or loss: €4 million in the first half of 2021, and €1 million in 2020 (all of which was reclassified in the first half of 2020). (c) Amount of cumulative currency translation differences associated with the equity investment in Regeneron, reclassified to profit or loss in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates).

Debt, Cash and Cash Equivalents

Debt, Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2021
Financial Instruments [Abstract]
Debt, Cash and Cash Equivalents	B.9. DEBT, CASH AND CASH EQUIVALENTS Changes in financial position during the period were as follows: (€ million) June 30, 2021 December 31, 2020 Long-term debt 17,935 19,745 Short-term debt and current portion of long-term debt 2,225 2,767 Interest rate and currency derivatives used to manage debt 70 119 Total debt 20,230 22,631 Cash and cash equivalents (9,722) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents (41) 74 Net debt (a) 10,467 8,790 (a) Net debt does not include lease liabilities, which amounted to €1,489 million as of June 30, 2021 and €1,163 million as of December 31, 2020. “Net debt” is a financial indicator used by management and investors to measure Sanofi’s overall net indebtedness. B.9.1. NET DEBT AT VALUE ON REDEMPTION A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2021 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2021 Amortized cost Adjustment to debt measured at fair value June 30, 2021 December 31, 2020 Long-term debt 17,935 64 (15) 17,984 19,794 Short-term debt and current portion of long-term debt 2,225 (2) 2 2,225 2,767 Interest rate and currency derivatives used to manage debt 70 — 17 87 142 Total debt 20,230 62 4 20,296 22,703 Cash and cash equivalents (9,722) — — (9,722) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents (41) — — (41) 74 Net debt (a) 10,467 62 4 10,533 8,862 (a) Net debt does not include lease liabilities, which amounted to €1,489 million as of June 30, 2021 and €1,163 million as of December 31, 2020. The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2021 December 31, 2020 non-current current Total non-current current Total Bond issues 17,897 1,938 19,835 19,698 2,280 21,978 Other bank borrowings 87 133 220 96 200 296 Other borrowings — 2 2 — 2 2 Bank credit balances — 152 152 — 285 285 Interest rate and currency derivatives used to manage debt — 87 87 57 85 142 Total debt 17,984 2,312 20,296 19,851 2,852 22,703 Cash and cash equivalents — (9,722) (9,722) — (13,915) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents — (41) (41) 6 68 74 Net debt 17,984 (7,451) 10,533 19,857 (10,995) 8,862 Principal financing and debt reduction transactions during the period Sanofi did not carry out any bond issues in the first half of 2021. Two bond issues were redeemed during the first half of 2021: a. a March 2011 fixed-rate bond issue of $2 billion, which matured on March 29, 2021; and b. a September 2015 bond issue of €500 million, redeemed on June 22, 2021 ahead of the contractual maturity date. Sanofi had the following arrangements in place as of June 30, 2021 to manage its liquidity in connection with current operations: • a syndicated credit facility of €4 billion, drawable in euros and in US dollars, the maturity of which was extended to December 4, 2022 following the exercise of a second extension option in June 2021, and which includes a further one-year extension option; and • a syndicated credit facility of €4 billion, drawable in euros and in US dollars, expiring December 2025, which includes two further extension options of one year each. As of June 30, 2021, there were no drawdowns under either facility. Sanofi also has a €6 billion Negotiable European Commercial Paper program in France and a $10 billion Commercial Paper program in the United States. During the first half of 2021 only the US program was used, with an average drawdown of $1.2 billion. The financing in place as of June 30, 2021 at the level of the holding company (which manages most of Sanofi’s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating. B.9.2. MARKET VALUE OF NET DEBT The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2021 December 31, 2020 Market value 11,811 10,500 Value on redemption 10,533 8,862

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2021
Financial Instruments [Abstract]
Derivative Financial Instruments	B.10. DERIVATIVE FINANCIAL INSTRUMENTS B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES The table below shows operating currency hedging instruments in place as of June 30, 2021. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2021 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 3,777 (43) 3,777 (43) of which US dollar 1,558 (30) 1,558 (30) of which Chinese yuan renminbi 628 (8) 628 (8) of which Singapore dollar 210 (2) 210 (2) of which Japanese yen 145 (1) 145 (1) of which Mexican peso 89 (2) 89 (2) Forward currency purchases 2,068 28 2,068 28 of which US dollar 1,059 21 1,059 21 of which Singapore dollar 406 6 406 6 of which Pound sterling 61 — 61 — of which Hungarian forint 53 — 53 — of which Chinese yuan renminbi 50 1 50 1 Total 5,845 (15) 5,845 (15) The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June 30, 2021 and recognized in the balance sheet at that date. Gains and losses on hedging in struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of 2021 . B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE The cash pooling arrangements for foreign subsidiaries outside the euro zone, and some of Sanofi’s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e. the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower). That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi’s debt once those instruments are taken into account. The table below shows financial currency hedging instruments in place as of June 30, 2021. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2021 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 5,525 (78) of which US dollar 4,203 (a) (66) 2022 of which Mexican peso 266 (7) 2021 of which Brazilian real 102 (b) (5) 2022 Forward currency purchases 7,984 30 of which US dollar 4,347 (c) (d) 14 2022 of which Singapore dollar 3,018 (e) 12 2022 of which Japanese yen 295 1 2021 Total 13,509 (48) (a) Includes forward sales with a notional amount of $3,615 million expiring in 2021, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2021, the fair value of these forward contracts represented a liability of €57 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (b) Includes forward sales with a notional amount of BRL 600 million expiring in 2022, designated as a hedge of Sanofi’s net investment in Medley Farmaceutica. As of June 30, 2021, the fair value of these forward contracts represented a liability of €7 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (c) Includes forward purchases with a notional amount of $1,000 million expiring in 2021 and 2022 , designated as a fair value hedge of USD bond issues against fluctuations in the EUR/USD spot rate. As of June 30, 2021, the fair value of these contracts represented a liability of €5 million, with €0.3 million of that amount credited to Other comprehensive income to recognise the hedging cost. (d) Includes currency swaps with a notional amount of $1,000 million, receive 0.22% pay EUR -0.63% expiring in 2022, designated as a cash flow hedge of $1,000 million of bond issues. As of June 30, 2021, the fair value of the swaps was a liability of €13 million. (e) Includes forward purchases with a notional amount of SGD 1,870 million expiring in 2021, design ated as fair value hedges of an equivalent portion of an intra-group loan against fluctuations in the EUR/SGD spot rate. As of June 30, 2021 , the fair value of these contracts represented a liability of €2 million, of which €0.5 million was credited to Other comprehensive income to recognise the hedging cost. To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt. The table below shows instruments of this type in place as of June 30, 2021: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2021 2022 2023 2024 2025 and beyond Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized Eonia / receive 0.06% — 2,000 — — — 2,000 16 2,000 16 — — — pay -0.57% / receive capitalized Eonia — 600 — — — 600 3 — — 600 3 1 pay capitalized SOFR USD / receive 1.03% — — — — 422 422 1 422 1 — — — receive capitalized Eonia / pay 1.48% (a) — 42 57 — — 99 (3) 99 (3) — — — Total — 2,642 57 — 422 3,121 17 2,521 14 600 3 1 (a) These interest rate swaps hedge fixed-rate bonds with a nominal of €99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within “Loans, advances and other long-term receivables”. B.10.3. EQUITY DERIVATIVES During 2019, Sanofi contracted derivative instruments (collars) on 593,712 shares of Dexcom, Inc. The collars were designated as fair value hedges of the Dexcom shares, and had a fair value as of June 30, 2021 of €29 million, recognized in full within Other comprehensive income .

Liabilities Related to Business

Liabilities Related to Business Combinations and to Non-Controlling Interest	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Liabilities Related to Business Combinations and to Non-Controlling Interest	B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS For a description of the nature of the liabilities reported in the line item Liabilities related to business combinations and to non-controlling interests , refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2020. The liabilities related to business combinations and to non-controlling interests shown in the table below are level 3 instruments under the IFRS 7 fair value hierarchy (see Note A.5.). Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2021 are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Other (b) Total (a) Balance at January 1, 2021 104 312 189 605 New transactions — — 17 17 Payments made (7) — (147) (154) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (c) (20) 20 (29) (29) Other movements — — — — Currency translation differences 2 4 2 8 Balance at June 30, 2021 79 336 32 447 Of which: • Current portion 200 • Non-current portion 247 (a) As of January 1, 2021, this comprised a non-current portion of €387 million and a current portion of €218 million. (b) The contingent consideration liability due to True North Therapeutics as a result of Sanofi’s acquisition of Bioverativ was settled in the first half of 2021. (c) Amounts mainly reported within the income statement line item Fair value remeasurement of contingent consideration. As of June 30, 2021, Liabilities related to business combinations and to non-controlling interests mainly comprised: • The Bayer contingent consideration liability arising from the acquisition of Genzyme in 2011. As of June 30, 2021, Bayer was still entitled to receive the following potential payments: – a percentage of sales of alemtuzumab up to a maximum of $1,250 million or over a maximum period of 10 years, whichever is achieved first; – milestone payments based on specified levels of worldwide sales of alemtuzumab beginning in 2021. The fair value of this liability was measured at €79 million as of June 30, 2021, versus €104 million as of December 31, 2020. The fair value of the Bayer liability is determined by applying the above contractual terms to sales projections which have been weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Bayer liability would increase by approximately 1%. • The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to €336 million as of June 30, 2021 versus €312 million as of December 31, 2020. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales projections. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately 2%.

Non-Current Provisions

Non-Current Provisions	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Non-Current Provisions	B.12. NON-CURRENT PROVISIONS The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2021 3,497 879 868 1,975 7,219 Increases in provisions and other liabilities 107 87 4 90 288 Provisions utilized (63) (74) (4) (58) (199) Reversals of unutilized provisions (4) (1) (1) (83) (a) (89) Transfers (3) (2) (159) (b) (28) (192) Net interest related to employee benefits, and unwinding of discount 22 1 — 4 27 Currency translation differences 37 13 1 16 67 Actuarial gains and losses on defined-benefit plans (328) — — — (328) Balance at June 30, 2021 3,265 903 709 1,916 6,793 (a) Amounts charged during the first half of 2021 relate mainly to provisions for products, litigation and other liabilities. (b) This movement includes transfers between current and non-current. Provisions for pensions and other post-employment benefits For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2020, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2020. The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the euro zone, the United States and the United Kingdom were reviewed as of June 30, 2021 to take into account changes during the first half of the year. Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Actuarial gains/(losses) on plan assets (24) 308 696 Actuarial gains/(losses) on benefit obligations 352 (a) (454) (b) (963) (a) Includes the effects of (i) the change in discount rates (in a range between +0.50% and +0.30%) and (ii) the change in the inflation rate in the United Kingdom (+0.20%) and in the Eurozone (+0.25%) in the first half of 2021. (b) Includes the effects of (i) the change in the discount rate in the United Kingdom and the United States (-0.50%) and (ii) the change in the inflation rate in the United Kingdom (-0.05%) in the first half of 2020.

Off Balance Sheet Commitments

Off Balance Sheet Commitments	6 Months Ended
	Jun. 30, 2021
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Off Balance Sheet Commitments	B.13. OFF BALANCE SHEET COMMITMENTS Off balance sheet commitments to third parties as of December 31, 2020 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2020. The principal commitments entered into, amended or discontinued during the period are described below: ▪ In January 2021, Sanofi entered into a license agreement with Biond Biologics, a biopharmaceutical company developing novel immunotherapies for cancer and a platform enabling the intra-cellular delivery of biologics, for the development and commercialization of BND-22 (a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, in development for the treatment of solid tumors). Under the terms of the agreement, Sanofi made an upfront payment of $125 million, and could pay up to $1 billion contingent on the attainment of certain objectives. ▪ On April 8, 2021, Sanofi acquired the entire share capital of Kymab (see Note B.1). The acquisition price includes milestone payments of up to $350 million contingent on the attainment of certain development objectives. ▪ On April 9, 2021, Sanofi acquired Tidal Therapeutics (see Note B.1). The acquisition price includes milestone payments of up to $310 million contingent on the attainment of certain development objectives. ▪ On April 16, 2021, Sanofi acquired Kiadis company, thereby terminating the 2020 license agreement.

Litigation and Arbitration Proc

Litigation and Arbitration Proceedings	6 Months Ended
	Jun. 30, 2021
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Litigation and Arbitration Proceedings	B.14. LITIGATION AND ARBITRATION PROCEEDINGS Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. The matters discussed below constitute the most significant developments since publication of the disclosures concerning legal proceedings in the Company’s financial statements for the year ended December 31, 2020. B.14.1. PRODUCTS ZANTAC ® LITIGATION IN THE US On June 30 and July 8, 2021, the Federal MDL Court entered orders granting in part and denying in part Defendants’ motions to dismiss various aspects of Plaintiffs’ amended complaints. The rulings significantly narrowed the scope of plaintiffs’ complaints and saw the dismissal of all retailers and generic manufacturers from the MDL, leaving branded manufacturers GSK, Pfizer, Boehringer Ingelheim, and Sanofi as the defendants. As of the end of June 2021, there were 1,321 personal injury cases in the MDL, comprising 1,753 personal injury plaintiffs alleging claims against Sanofi. Separately, and as of the end of June 2021, there were 54 cases pending in California state court comprising 1,063 plaintiffs. Other cases are pending in various state courts. These state court cases still include numerous retail and generics manufacturing defendants in addition to branded manufacturers. Overall between State and federal filings there are currently 1,501 product liability “complaints” filed. These complaints encompass 2,878 individual product liability “plaintiffs” who have all filed against Sanofi. Additional cases may be filed. It is not possible, at this stage, to assess reliably the outcome of these lawsuits or the potential financial impact on Sanofi. DEPAKINE ® PRODUCT LITIGATION IN FRANCE Administrative Actions In July 2020, a court had recognized the responsibility of the State in 3 administrative proceedings initiated by families against the State. In March 2021, the Administrative Court did not retain any lack of information of the mother regarding the risk of neurodevelopmental disorders at the time of pregnancies occurred in 1998 and in 2001, based on the state of scientific knowledge at these dates. However, liabilities were retained against the State, the healthcare professionals and Sanofi, notably for discrepancy between the SmPC (Summary of the Product Characteristics) and the patient leaflet regarding the risk of malformations. Given that Sanofi-Aventis France (SAF) was not a party to these administrative proceedings, SAF’s arguments (i.e. notably several requests from SAF to the Health Authorities to reinforce warnings to healthcare professionals and patients in relation to Depakine ® ) were not considered. SAF has filed requests for voluntary intervention in these proceedings to present its arguments before the Administrative Court of Appeal. Civil Proceedings On July 21, 2021, a Judicial Tribunal in France dismissed a claim for damages brought against SAF regarding a child born in 1995. The Judicial Tribunal considered that the risk of occurrence of neurodevelopmental disorders in children born to mother exposed to sodium valproate during pregnancy was not evidenced by the state of scientific knowledge at the time of her pregnancy. This decision might be appealed. B.14.2. PATENTS RAMIPRIL ® CANADA PATENT LITIGATION At the request of the parties, in June 2021, the Court ordered that the action be stayed in view of the lower court's decision in March in the Apotex vs. Lilly case. In the Lilly case, the Court dismissed Apotex's Statute of Monopolies claim by way of summary judgment. If upheld on appeal, this decision may end Apotex's claim against Sanofi, also based on the Statute of Monopolies. It is anticipated that the appeals process, through finality will take approximately 24 months. PRALUENT ® (ALIROCUMAB)-RELATED AMGEN PATENT LITIGATION IN THE US In April 2021, Amgen filed a petition with the Court of Appeals for the Federal Circuit (“CAFC”) seeking rehearing of the February 2021 ruling. In June 2021, the CAFC denied Amgen’s petition for rehearing. DUPIXENT ® (DUPILUMAB)-RELATED AMGEN INTER PARTES REVIEWS AND PATENT LITIGATION IN THE US Amgen filed a Petition for Writ of Certiorari to the U.S. Supreme Court challenging the Federal Circuit’s affirmance that all claims of U.S. Patent No. 8,679,487 are invalid, which petition the Court denied in June 2021. Amgen’s ‘487 patent is invalid with no further possibility of appeal. The associated district court case should be dismissed in the near term, bringing all US patent disputes involving Dupixent ® to a close. B.14.3. OTHER LITIGATION PLAVIX ® (clopidogrel) - ATTORNEY GENERAL ACTION IN HAWAII In February 2021, the Court issued its decision, imposing penalties in the total amount of $834,012,000 against both Sanofi and Bristol Myers Squibb (BMS), with $417,006,000 being apportioned to each company. In June 2021, Sanofi and BMS appealed this judgment. To the extent this judgment or possibly a reduced judgment remains after the appeal, the judgment would be split evenly with BMS. PLAVIX ® (clopidogrel) - ATTORNEY GENERAL ACTION IN NEW MEXICO In September 2016, the New Mexico Attorney General (AG) filed a complaint, claiming that Sanofi and Bristol Meyers Squibb (BMS) engaged in unfair and deceptive practices related to the marketing and labelling of Plavix ® . The New Mexico AG specifically alleged that Plavix ® had a diminished effect in patients of certain genetic backgrounds and that the Companies failed to make an earlier disclosure of this information. Discovery is underway, with a jury trial set on the court’s April 2022 trial docket. 340-B DRUG PRICING PROGRAM IN THE UNITED STATES Sanofi is currently involved in a number of matters relating to the 340B Drug Pricing Program (a US federal program that requires drug manufacturers to supply certain products to healthcare authorities at reduced prices) in the United States. In two of those matters, one filed in October 2020 in the United States District Court for the District of Columbia, and one in December 2020 in the US District Court for the Northern District of California, certain 340B Covered Entities and advocacy groups filed lawsuits against the US Department of Health and Human Services (“HHS”), its Secretary, its agency the Health Resources and Services Administration (“HRSA”), and HRSA’s administrator alleging that the 340B statute requires drug manufacturers, like Sanofi, to supply Contract Pharmacies with drugs discounted under the 340B Program and prohibits manufacturers from imposing conditions on the provision of such drugs to Contract Pharmacies. Plaintiffs seek, in these actions, to have the defendant agencies and their officials enforce plaintiffs’ interpretation of the 340B statute. Sanofi, along with certain other drug manufacturers, have filed a motion to intervene in these lawsuits. The lawsuit pending in the District of Columbia is currently stayed and the lawsuit pending in the Northern District of California was dismissed without prejudice. In January 2021, an advocacy group, on behalf of a number of Covered Entities, filed an Administrative Dispute Resolution (“ADR”) proceeding before HRSA against Sanofi and two other drug manufacturers seeking to require the named manufacturers to supply Contract Pharmacies with drugs discounted under the 340B Program without imposing conditions. In February 2021, the Vermont Attorney General issued a Civil Investigative Subpoena seeking certain information about Sanofi’s 340B program participation. In addition to these matters, in January 2021, Sanofi filed a lawsuit against HHS, its Secretary, its General Counsel, HRSA, and HRSA’s administrator in the US District Court for the District of New Jersey. Sanofi’s lawsuit challenges: (i) under the Administrative Procedure Act, an Advisory Opinion issued by the HHS Office of General Counsel on December 30, 2020, which concludes that drug manufacturers are legally obligated to provide drugs discounted under the 340B program to Contract Pharmacies and that drug manufacturers may not impose conditions on the provision of such drugs to Contract Pharmacies; and (ii) under the United States Constitution and the Administrative Procedure Act, an ADR Rule, issued by HHS on December 10, 2020, which establishes certain procedures for disputes between Covered Entities and drug manufacturers participating in the 340B Program. On February 2, 2021, Sanofi filed a motion for a preliminary injunction, seeking to enjoin the ADR Rule on the basis of Sanofi’s constitutional injuries. On March 16, 2021, while Sanofi’s motion was still pending, a district court in the Southern District of Indiana granted the drug manufacturer Eli Lilly’s motion for a preliminary injunction against the ADR Rule. On April 19, 2021, the government filed a motion to dismiss the amended complaint and for summary judgment. On May 17, 2021, the HRSA sent Sanofi a letter indicating that HRSA had determined that Sanofi’s initiative violates Section 340B and that Sanofi had overcharged certain covered entities. HRSA’s letter threatened Sanofi with enforcement actions, including civil monetary penalties (“CMPs”), if Sanofi continued to operate its initiative. Five other manufacturers received a similar letter. On June 1, 2021, Sanofi sent a response to HRSA stating that the legality of Sanofi’s initiative was being litigated in court and explaining why it complies with the 340B statute, why HRSA’s letter violates the Administrative Procedure Act (“APA”) and why CMPs would be inappropriate.

Other Operating Income And Expe

Other Operating Income And Expenses	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Other Operating Income and Expenses	B.15. OTHER OPERATING INCOME AND EXPENSES Other operating income amounted to €409 million in the first half of 2021 (versus €281 million in the first half of 2020), and Other operating expenses to €709 million (versus €693 million in the first half of 2020). The main items included in Other operating income in the first half of 2021 were: (i) income from pharmaceutical partners of €100 million (versus €92 million in the first half of 2020), of which €88 million came from Regeneron (versus €79 million in the first half of 2020, see table below); (ii) gains on disposals of assets and operations of €156 million, primarily on divestments of mature products (versus €147 million in the first half of 2020); and (iii) a payment of €119 million from Daiichi Sankyo relating to the ending of a collaboration on vaccines in Japan. Other operating expenses for the first half of 2021 included €643 million of expenses relating to the alliance with Regeneron (versus €525 million in the first half of 2020), as shown in the table below. (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance (521) (341) (727) Additional share of profit paid by Regeneron towards development costs 51 35 75 Reimbursement to Regeneron of selling expenses incurred (116) (176) (349) Total: Monoclonal Antibody Alliance (586) (482) (1,001) Immuno-Oncology Alliance 37 44 89 Other (mainly Zaltrap ® ) (6) (8) (14) Other operating income/(expenses), net related to Regeneron Alliance (555) (446) (926) of which amount presented in Other operating income 88 79 164

Restructuring Costs and Similar

Restructuring Costs and Similar Items	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Restructuring Costs and Similar Items	B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS Restructuring costs and similar items comprise the following: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Employee-related expenses 72 642 690 Charges, gains or losses on assets (a) 65 62 149 Compensation for early termination of contracts (other than contracts of employment) 10 11 40 Decontamination costs — — (2) Other restructuring costs 180 43 187 Total 327 758 1,064 (a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.

Other Gains and Losses, and Lit

Other Gains and Losses, and Litigation	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Other Gains and Losses, and Litigation	B.17. OTHER GAINS AND LOSSES, AND LITIGATION No items were recorded within Other gains and losses, and litigation in the first half o f 2021. This compares with a net gain of €136 million in the first half of 2020, mainly comprising a gain on the sale of operations related to the Seprafilm ® product.

Financial Expenses and Income

Financial Expenses and Income	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Financial Expenses and Income	B.18. FINANCIAL EXPENSES AND INCOME An analysis of financial expenses and income is set forth below: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Cost of debt (a) (168) (166) (328) Interest income (b) 30 66 103 Cost of net debt (138) (100) (225) Non-operating foreign exchange gains/(losses) 4 2 (6) Unwinding of discounting of provisions (c) (5) (6) (11) Net interest cost related to employee benefits (23) (32) (59) Gains/(losses) on disposals of financial assets 3 — 6 Net interest expense on lease liabilities (15) (19) (38) Other 13 (12) (4) Net financial income/(expenses) (161) (167) (337) comprising: Financial expenses (189) (198) (390) Financial income 28 31 53 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €5 million in the first half of 2021, €58 million in the first half of 2020, and €93 million over the whole of 2020. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €28 million in the first half of 2021, €37 million in the first half of 2020, and €66 million over the whole of 2020. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). The impact of the ineffective portion of hedging relationships was not material in either 2021 or 2020.

Income Tax Expense

Income Tax Expense	6 Months Ended
	Jun. 30, 2021
Income Taxes [Abstract]
Income Tax Expense	B.19. INCOME TAX EXPENSE Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States. The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Current taxes (806) (1,127) (1,912) Deferred taxes 124 133 99 Total (682) (994) (1,813) Income before tax and investments accounted for using the equity method 3,452 9,941 13,804 The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2021 (6 months) (a) June 30, 2020 (6 months) (a) December 31, 2020 (12 months) Standard tax rate applicable in France 28.4 32.0 32.0 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (10.1) (20.2) (18.2) Revisions to tax exposures and settlements of tax disputes 1.0 0.2 0.5 Fair value remeasurement of contingent consideration liabilities 0.2 (0.1) — Other (c) 0.3 (1.9) (1.2) Effective tax rate 19.8 10.0 13.1 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For 2020, this line includes the difference between the standard French tax rate and the tax rate applicable to the gain on divestment of Regeneron shares. (c) In determining the amount of the deferred tax liability for 2020, Sanofi look into account changes in the ownership structure of certain subsidiaries.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Operating Segments [Abstract]
Segment Information	B.20. SEGMENT INFORMATION As indicated in Note B.26. to the consolidated financial statements for the year ended December 31, 2020, Sanofi has three operating segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Pharmaceuticals segment comprises, for all geographical territories, the commercial operations of the following global franchises: Specialty Care (Dupixent ® , Neurology & Immunology, Rare Diseases, Oncology, and Rare Blood Disorders) and General Medicines (Diabetes, Cardiovascular, and Established Prescription Products), together with research, development and production activities dedicated to the Pharmaceuticals segment. This segment also includes associates whose activities are related to pharmaceuticals. Following the transaction of May 29, 2020, Regeneron is no longer an associate of Sanofi (see Note D.1. to our consolidated financial statements for the year ended December 31, 2020). Consequently, the Pharmaceuticals segment no longer includes Sanofi’s equity-accounted share of Regeneron’s profits for all the periods presented in that note. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. Inter-segment transactions are not material. The costs of Sanofi’s global support functions (External Affairs, Finance, Human Resources, Legal Affairs, Information Solutions & Technologies, Sanofi Business Services, etc.) are mainly managed centrally at group-wide level. The costs of those functions are presented within the “Other” category. That category also includes other reconciling items such as retained commitments in respect of divested activities. Following the Capital Markets Day held in February 2021, Sanofi changed the presentation of net sales within the General Medicines and Consumer Healthcare GBUs, and also reallocated certain expenses. In particular, IT costs relating to our new digital organization – previously allocated to the Pharmaceuticals, Vaccines, and Consumer Healthcare segments – are now included within the “Other” segment. The 2020 segmental results presented below have been amended for comparative purposes in order to reflect those adjustments. B.20.1. SEGMENT RESULTS B.20.1.1. Analysis of net sales The table below sets forth net sales for the six months ended June 30, 2021 and June 30, 2020: (€ million) Europe United States Other countries June 30, 2021 Europe United States Other countries June 30, 2020 Pharmaceuticals 3,575 4,892 4,729 13,196 3,347 4,806 4,867 13,020 General Medicines 2,228 1,262 3,728 7,218 2,232 1,458 3,928 7,618 of which Lantus ® 246 429 614 1,289 281 474 662 1,417 Toujeo ® 195 120 185 500 188 143 165 496 Praluent ® 75 5 24 104 56 68 22 146 Multaq ® 12 132 7 151 12 135 7 154 Lovenox ® 368 15 385 768 298 15 317 630 Plavix ® (1) 60 5 420 485 66 4 438 508 Generics (1) 4 70 320 394 5 75 341 421 Specialty Care 1,347 3,630 1,001 5,978 1,115 3,348 939 5,402 of which Aubagio ® 264 666 64 994 231 775 62 1,068 Cerezyme ® 124 83 136 343 125 90 153 368 Myozyme/Lumizyme ® 200 180 103 483 193 178 101 472 Fabrazyme ® 111 190 111 412 98 206 109 413 Eloctate ® — 216 62 278 — 234 96 330 Jevtana ® 75 119 46 240 92 123 56 271 Dupixent ® 289 1,740 261 2,290 174 1,310 150 1,634 Vaccines 244 626 1,067 1,937 281 491 1,064 1,836 of which Polio/Pertussis/Hib vaccines 145 241 667 1,053 162 183 714 1,059 Influenza vaccines 18 — 178 196 5 13 161 179 Consumer Healthcare (2) 653 570 979 2,202 717 583 1,024 2,324 of which Allergy 34 200 109 343 36 214 131 381 Pain Care 250 91 187 528 244 98 207 549 Digestive Wellness 200 61 312 573 192 36 263 491 Total net sales 4,472 6,088 6,775 17,335 4,345 5,880 6,955 17,180 (1) Sanofi has altered the presentation of net third-party sales by franchise at the level of the General Medicines GBU. Industrial sales (primarily of active ingredients and semi-finished products) to third parties such as CMOs are now grouped together separately. Previously, such sales were presented within the Diabetes franchise and the Cardiovascular & Established Prescription Products franchises, on the line for the relevant product. (2) For the Consumer Healthcare GBU, Sanofi has adopted a more granular presentation by introducing new sub-categories that reflect consumer trends and the strengths and opportunities of the portfolio. B.20.1.2. Business operating income Sanofi reports segment results on the basis of “Business operating income”, a non-GAAP financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources. Certain costs have been reclassified from operating segments to the “Other” segment for 2020. “Business operating income” is derived from Operating income , adjusted as follows: • the amounts reported in the line items Restructuring costs and similar items, Fair value remeasurement of contingent consideration (relating to business combinations or divestments) and Other gains and losses, and litigation are eliminated; • amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; • the share of profits/losses from investments accounted for using the equity method is added (for 2020, this excludes Regeneron for the period to May 29, 2020 - see Note D.1. to the consolidated financial statements for the year ended December 31, 2020); • net income attributable to non-controlling interests is deducted; • other acquisition-related effects (primarily the workdown of acquired inventories remeasured at fair value at the acquisition date, and the impact of acquisitions on investments accounted for using the equity method) are eliminated; • restructuring costs relating to investments accounted for using the equity method are eliminated; and • for 2020, the gain on the divestment of Regeneron shares dated May 29, 2020 is eliminated (this elimination does not include the gain on the remeasurement of the 400,000 retained shares at market value as of that date). Segment results are shown in the table below: June 30, 2021 (6 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 13,196 1,937 2,202 — 17,335 Other revenues 108 461 27 — 596 Cost of sales (3,403) (1,254) (753) (131) (5,541) Research and development expenses (2,041) (316) (69) (237) (2,663) Selling and general expenses (2,480) (359) (700) (991) (4,530) Other operating income and expenses (466) 121 23 22 (300) Share of profit/(loss) from investments accounted for using the equity method 13 8 5 — 26 Net income attributable to non-controlling interests (16) — (4) — (20) Business operating income 4,911 598 731 (1,337) 4,903 June 30, 2020 (6 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 13,020 1,836 2,324 — 17,180 Other revenues 70 474 30 — 574 Cost of sales (3,406) (1,176) (781) (144) (5,507) Research and development expenses (2,065) (319) (69) (239) (2,692) Selling and general expenses (2,388) (369) (744) (1,106) (4,607) Other operating income and expenses (150) 4 21 (130) (255) Share of profit/(loss) from investments accounted for using the equity method 4 — 7 — 11 Net income attributable to non-controlling interests (17) — (4) — (21) Business operating income (a) 5,068 450 784 (1,619) 4,683 (a) 2020 figures have been adjusted to take account of the reallocation of certain expenses (in particular IT costs related to Sanofi’s new digital organization) from the Pharmaceuticals, Vaccines and Consumer Healthcare operating segments to the “Other” segment. December 31, 2020 (12 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 25,674 5,973 4,394 — 36,041 Other revenues 128 1,141 59 — 1,328 Cost of sales (6,980) (3,312) (1,528) (284) (12,104) Research and development expenses (4,170) (682) (153) (524) (5,529) Selling and general expenses (4,926) (789) (1,419) (2,256) (9,390) Other operating income and expenses (490) 4 53 (129) (562) Share of profit/(loss) from investments accounted for using the equity method 5 2 9 — 16 Net income attributable to non-controlling interests (33) — (5) — (38) Business operating income (a) 9,208 2,337 1,410 (3,193) 9,762 (a) 2020 figures have been adjusted to take account of the reallocation of certain expenses (in particular IT costs related to Sanofi’s new digital organization) from the Pharmaceuticals, Vaccines and Consumer Healthcare operating segments to the “Other” segment. The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Business operating income 4,903 4,683 9,762 Share of profit/(loss) from investments accounted for using the equity method (a) (26) (11) (16) Net income attributable to non-controlling interests (b) 20 21 38 Amortization and impairment of intangible assets (953) (1,206) (2,011) Fair value remeasurement of contingent consideration (4) 54 124 Expenses arising from the impact of acquisitions on inventories — (36) (53) Restructuring costs and similar items (327) (758) (1,064) Other gains and losses, and litigation (c) — 136 136 Gain on divestment of Regeneron shares on May 29, 2020 (d) — 7,225 7,225 Operating income 3,613 10,108 14,141 Financial expenses (189) (198) (390) Financial income 28 31 53 Income before tax and investments accounted for using the equity method 3,452 9,941 13,804 (a) Excludes (i) restructuring costs and (ii) expenses arising from the impact of acquisitions on investments accounted for using the equity method. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) For 2020, this line mainly comprises the gain on the sale of operations related to the Seprafilm ® product to Baxter. (d) For 2020, this line includes the gain on the sale of (i) 13 million shares of Regeneron common stock in the registered public offering and (ii) the 9.8 million shares repurchased by Regeneron, but does not include the gain arising from the remeasurement of the 400,000 retained shares at market value of May 29, 2020. B.20.2. OTHER SEGMENT INFORMATION The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets. The principal investments accounted for using the equity method in the Pharmaceuticals segment are entities majority owned by MSP Vaccine Company, and Infraserv GmbH & Co. Höchst KG (see Note B.5.). Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2021 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 144 70 — 214 Acquisitions of property, plant and equipment 445 196 27 668 Acquisitions of other intangible assets 263 81 6 350 June 30, 2020 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 149 44 3 196 Acquisitions of property, plant and equipment 294 181 27 502 Acquisitions of other intangible assets 153 21 6 180 December 31, 2020 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 154 47 — 201 Acquisitions of property, plant and equipment 755 404 95 1,254 Acquisitions of other intangible assets 532 322 6 860 B.20.3. INFORMATION BY GEOGRAPHICAL REGION The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2021 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,335 4,472 1,087 6,388 6,088 6,475 Non-current assets: • property, plant and equipment 9,503 5,874 3,162 2,699 1,996 930 • goodwill 44,979 — — — — — • other intangible assets 19,466 7,272 — 10,895 — 1,299 June 30, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,180 4,345 1,061 6,151 5,880 6,684 Non-current assets: • property, plant and equipment 9,368 5,683 3,067 2,756 2,153 929 • goodwill 45,254 — — — — — • other intangible assets 17,021 6,544 — 8,838 — 1,639 December 31, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 36,041 9,151 2,223 14,060 13,465 12,830 Non-current assets: • property, plant and equipment 9,365 5,895 3,189 2,542 1,899 928 • goodwill 44,364 — — — — — • other intangible assets 18,421 6,278 — 10,675 — 1,468 As stated in Notes B.6.1. and D.5. to the consolidated financial statements for the year ended December 31, 2020, goodwill is not allocated by geographical region. B.20.4. PRINCIPAL CUSTOMERS AND CREDIT RISK Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 24% of net sales in the first half of 2021. Sanofi’s three largest customers respectively accounted for approximately 11%, 8% and 5% of consolidated net sales in the first half of 2021, mostly in the Pharmaceuticals segment (versus approximately 9%, 6% and 5% in the first half of 2020).

Events Subsequent to June 30, 2

Events Subsequent to June 30, 2021	6 Months Ended
	Jun. 30, 2021
Disclosure of non-adjusting events after reporting period [abstract]
Events Subsequent to June 30, 2021	C/ EVENTS SUBSEQUENT TO JUNE 30, 2021 On July 15, 2021, Sanofi and Kiadis Pharma N.V. announced that the conversion of Kiadis from a public limited liability company into a private limited liability company, following the delisting of Kiadis shares on Euronext Amsterdam and Euronext Brussels on May 25, 2021 and the resolution adopted by the company’s shareholders at the General Meeting of March 30, 2021 would be postponed until the end of the statutory buy-out procedure initiated by Sanofi at the end of the initial tender offer acceptance period.

Basis of Preparation of the H_2

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Corporate Information And Statement Of IFRS Compliance [Abstract]
International Financial Reporting Standards (IFRS)	A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS) The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2021 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2021 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2021 are identical to those presented in the consolidated financial statements for the year ended December 31, 2020. As a reminder, Sanofi early adopted the Phase 2 amendment to IFRS 9 relating to interest rate benchmark reform in its consolidated financial statements for the year ended December 31, 2020.
Use of Estimates	A.2. USE OF ESTIMATES The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment and intangible assets; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of financial assets at amortized cost; • the amount of post-employment benefit obligations; • the amount of liabilities or provisions for restructuring, litigation, tax risks and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences. Actual results could differ from these estimates.
Seasonal Trends	A.3. SEASONAL TRENDS Sanofi’s activities are not subject to significant seasonal fluctuations.
Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies	A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES In 2021, Sanofi continues to account for subsidiaries in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. In 2018, following a change to the foreign exchange system, the “DICOM” rate was replaced by the “PETRO” rate (with a floating US dollar/bolivar parity) and the strong bolivar (“VEF”) by a new currency known as the sovereign bolivar (“VES”), reflecting a 1-for-100,000 devaluation. Consequently, the contribution of the Venezuelan subsidiaries to the Sanofi consolidated financial statements is immaterial. In Argentina and Lebanon, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in those countries. Consequently, Sanofi has treated Argentina (since July 1, 2018) and Lebanon (since January 1, 2020) as hyperinflationary economies, and applied IAS 29. The impact on the financial statements of adjustments required for the application of IAS 29 in respect of Argentina and Lebanon as of June 30, 2021 is immaterial.
Fair Value of Financial Instruments	A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2020. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps (c) Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps (c) Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) The fair value of the Dexcom equity derivatives (see Note B.10.3) is classified as Level 2 because the valuation is based on a generally accepted technique (the Black & Scholes model) that uses inputs from directly observable market parameters (share price, risk free rate and implied volatility).
New Pronouncements Issued by IASB and Applicable from June 2021 or Later	A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM JULY 2021 OR LATER On February 12, 2021, the IASB issued an amendment to IAS 1 concerning accounting policy disclosures, and an amendment to IAS 8 concerning the definition of accounting estimates. On May 7, 2021, the IASB issued an amendment to IAS 12 concerning deferred tax related to assets and liabilities arising from a single transaction. Sanofi does not expect any material impact from the application of these two amendments, which are effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after January 1, 2023. Sanofi will not early adopt these amendments. On March 31, 2021, the IASB issued a second “Covid-19-Related Rent Concessions” amendment to IFRS 16, effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after July 1, 2021. The amendment enables lessees, subject to certain conditions, to opt out of the requirement to determine whether a Covid-19-related rent concession is a lease modification . Sanofi does not expect a material impact from the application of this amendment. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1. On May 14, 2020, the IASB issued “Reference to the Conceptual Framework”, an amendment to IFRS 3; “Proceeds before Intended Use”, an amendment to IAS 16; “Onerous Contracts – Cost of Fulfilling a Contract”, an amendment to IAS 37; and “Annual Improvements to IFRS standards 2018-2020”. Sanofi does not expect a material impact from those amendments, which are effective (subject to endorsement by the European Union) for annual reporting periods beginning on or after January 1, 2022. Sanofi will not early adopt these amendments . In its April 2021 update, the IFRS IC published an agenda decision clarifying how to calculate the obligation relating to certain defined benefit plans under which the retirement benefit is (i) contingent on the employee being employed by the entity at the time of retirement and (ii) capped at a specified number of years of service. The impacts of this decision on Sanofi are under review. In its March 2021 update, the IFRS IC published an agenda decision clarifying how to account for costs of configuring or customising a supplier’s application software in a Software as a Service (SaaS) arrangement. The impacts of this decision on Sanofi are under review.
COVID-19 Pandemic	A.7. COVID-19 PANDEMIC As a reminder, Covid-19 – confirmed as a pandemic by the World Health Organisation on March 11, 2020 – had no major impact on the Sanofi consolidated financial statements for the six months ended June 30, 2020 or the year ended December 31, 2020. Specifically, the pandemic did not create any uncertainties that appreciably called into question the estimates and assumptions made by management. In the first half of 2021, a return to normal activity levels was observed in the principal markets where Sanofi operates. Sanofi will continue to monitor the situation, and to update management’s estimates and assumptions accordingly. Effect of the Covid-19 pandemic on accounts receivable As of June 30, 2021, Sanofi has identified nothing that would indicate a material increase in expected credit risk, especially as regards its principal customers (see Note B.20.4). Effect of the Covid-19 pandemic on the liquidity position The Covid-19 pandemic did not have a negative impact on Sanofi’s liquidity position.
Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK	A.8. AGREEMENTS RELATING TO THE RECOMBINANT COVID-19 VACCINE CANDIDATE DEVELOPED BY SANOFI IN COLLABORATION WITH GSK On May 27, 2021, Sanofi and GlaxoSmithKline (GSK) initiated an international Phase III trial to evaluate the efficacy of their COVID-19 vaccine candidate. As of June 30, 2021, that new stage in the development of the vaccine candidate has not altered the funding commitments made by the United States during 2020, or the pre-orders placed by Canada, the United Kingdom or the European Union (see Note A.7. to the consolidated financial statements for the year ended December 31, 2020). Sanofi has recognized the US government funding as a deduction from the research and development expenses incurred, or from the acquisition cost of the property, plant and equipment acquired, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance).

Basis of Preparation of the H_3

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Corporate Information And Statement Of IFRS Compliance [Abstract]
Disclosure of detailed information about financial instruments	The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach Under IFRS 9, contingent consideration receivable on a divestment is a financial asset. The fair value of such assets is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2020. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets recognized under the fair value option (a) Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Debt Amortized cost (b) N/A N/A In the case of debt with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps (c) Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps (c) Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price N/A B.11. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) These assets are held to fund a deferred compensation plan offered to certain employees. (b) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). (c) The fair value of the Dexcom equity derivatives (see Note B.10.3) is classified as Level 2 because the valuation is based on a generally accepted technique (the Black & Scholes model) that uses inputs from directly observable market parameters (share price, risk free rate and implied volatility).

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Summary of Acquisitions and Capitalized Interest by Operating Segment	The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2021: (€ million) June 30, 2021 December 31, 2020 Acquisitions 523 1,310 Pharmaceuticals 356 831 Industrial facilities 232 634 Research sites 72 152 Other 52 45 Vaccines 140 384 Consumer Healthcare 27 95 Capitalized interest 6 11

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Intangible Assets [Abstract]
Schedule of Movements in Other Intangible Assets	Movements in other intangible assets during the first half of 2021 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2021 9,600 61,074 1,748 72,422 Changes in scope of consolidation (a) 1,337 82 — 1,419 Acquisitions and other increases 277 63 74 414 Disposals and other decreases — (68) (13) (81) Currency translation differences 229 803 12 1,044 Transfers (7) 10 (5) (2) Gross value at June 30, 2021 11,436 61,964 1,816 75,216 Accumulated amortization and impairment at January 1, 2021 (3,508) (49,345) (1,148) (54,001) Amortization expense — (797) (71) (868) Impairment losses, net of reversals (b) (137) (41) — (178) Disposals and other decreases 1 37 12 50 Currency translation differences (50) (693) (10) (753) Accumulated amortization and impairment at June 30, 2021 (3,694) (50,839) (1,217) (55,750) Carrying amount at January 1, 2021 6,092 11,729 600 18,421 Carrying amount at June 30, 2021 7,742 11,125 599 19,466 (a) See Note B.1. (b) See Note B.4.

Investments Accounted for Usi_2

Investments Accounted for Using the Equity Method (Tables)	6 Months Ended
	Jun. 30, 2021
Interests In Other Entities [Abstract]
Summary of Investments in Associates and Joint Ventures	Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2020), and comprise: (€ million) % interest June 30, 2021 December 31, 2020 Infraserv GmbH & Co. Höchst KG (a) 31.2 69 72 MSP Vaccine Company (b) 50.0 67 44 Other investments — 78 85 Total 214 201 (a) Joint venture. (b) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine B.V.
Summary of Principal Transactions and Balances with Related Parties	The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2021 June 30, 2020 December 31, 2020 Sales (a) 31 52 75 Royalties and other income (a) 26 65 97 Accounts receivable and other receivables 66 7 50 Purchases and other expenses (including research expenses) (a) 124 605 747 Accounts payable and other payables 17 5 15

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Summary of Other Non-current Assets	Other non-current assets comprise: (€ million) June 30, 2021 December 31, 2020 Equity instruments at fair value through other comprehensive income 669 588 Debt instruments at fair value through other comprehensive income 409 426 Other financial assets at fair value through profit or loss 836 890 Pre-funded pension obligations 179 177 Long-term prepaid expenses 77 92 Long-term loans and advances and other non-current receivables 508 537 Derivative financial instruments 21 24 Total 2,699 2,734

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Summary of Accounts Receivable	Accounts receivable break down as follows: (€ million) June 30, 2021 December 31, 2020 Gross value 6,932 7,633 Allowances (130) (142) Carrying amount 6,802 7,491
Summary of Gross Value of Overdue Receivables	The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2021 427 78 105 96 33 115 December 31, 2020 549 271 97 52 34 95

Consolidated Shareholders' Eq_2

Consolidated Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Share Capital, Reserves And Other Equity Interest [Abstract]
Summary of Treasury Shares Held	Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2021 8.25 0.655 % December 31, 2020 8.28 0.658 % June 30, 2020 2.59 0.207 % January 1, 2020 0.02 0.002 %
Summary of Characteristics of Employee Share Ownership Plans Awarded	Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2020. The principal features of the plans awarded in 2021 are set forth below: 2021 Type of plan Performance share plan Date of Board meeting approving the plan April 30, 2021 Total number of shares subject to a 3-year service period 3,484,420 Of which with no market condition 2,209,901 Fair value per share awarded (€) (a) 77.27 Of which with market condition 1,274,519 Fair value per share awarded (€) (b) 71.30 Fair value of plan at the date of grant (€ million) 262 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.
Summary of Number of Restricted Shares Not Yet Fully Vested	The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2021 June 30, 2020 Total expense for restricted share plans (€ million) 83 113 Number of shares not yet fully vested 9,996,495 10,900,815 Under 2021 plans 3,484,420 — Under 2020 plans 3,175,084 3,340,501 Under 2019 plans 3,252,099 3,545,507 Under 2018 plans 84,892 4,014,807
Summary of Options Outstanding and Exercisable	The table below provides summary information about options outstanding and exercisable as of June 30, 2021: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €50.00 to €60.00 per share 163,367 0.68 56.44 163,367 56.44 From €60.00 to €70.00 per share 168,784 6.85 65.84 — — From €70.00 to €80.00 per share 1,499,313 3.60 74.10 1,279,313 73.65 From €80.00 to €90.00 per share 634,184 4.86 89.19 634,184 89.19 Total 2,465,648 2,076,864
Summary of Number of Shares Used to Compute Diluted Earnings Per Share	Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Average number of shares outstanding 1,250.3 1,251.7 1,253.6 Adjustment for stock options with dilutive effect 0.3 0.4 0.4 Adjustment for restricted shares 5.0 6.1 6.1 Average number of shares used to compute diluted earnings per share 1,255.6 1,258.2 1,260.1
Summary of Movements within Other Comprehensive Income	Movements within other comprehensive income are shown below: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method 328 (146) (267) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — — (1) ▪ Tax effects (11) (19) 45 Equity instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) 70 365 358 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — (13) (14) ▪ Equity risk hedging instruments designated as fair value hedges (3) (53) (24) ▪ Tax effects (4) (70) (85) Items not subsequently reclassifiable to profit or loss 380 64 12 Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) (17) 4 15 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects 4 (1) (3) Cash flow hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) (4) 29 4 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects — (9) (2) Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) 1,171 (590) (3,872) ▪ Currency translation differences (investments accounted for using the equity method) (b) (3) 24 32 ▪ Currency translation differences related to the investment in Regeneron and reclassified to profit or loss (c) — (318) (318) ▪ Hedges of net investments in foreign operations (b) (107) (60) 180 ▪ Tax effects 30 19 (58) Items subsequently reclassifiable to profit or loss 1,074 (902) (4,022) (a) Includes reclassifications to profit or loss: €4 million in the first half of 2021, and €5 million in 2020. (b) Includes reclassifications to profit or loss: €4 million in the first half of 2021, and €1 million in 2020 (all of which was reclassified in the first half of 2020). (c) Amount of cumulative currency translation differences associated with the equity investment in Regeneron, reclassified to profit or loss in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates).

Debt, Cash and Cash Equivalen_2

Debt, Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2021
Financial Instruments [Abstract]
Summary of Changes in Financial Position	Changes in financial position during the period were as follows: (€ million) June 30, 2021 December 31, 2020 Long-term debt 17,935 19,745 Short-term debt and current portion of long-term debt 2,225 2,767 Interest rate and currency derivatives used to manage debt 70 119 Total debt 20,230 22,631 Cash and cash equivalents (9,722) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents (41) 74 Net debt (a) 10,467 8,790 (a) Net debt does not include lease liabilities, which amounted to €1,489 million as of June 30, 2021 and €1,163 million as of December 31, 2020.
Summary of Reconciliation of Carrying Amount to Value on Redemption	A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2021 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2021 Amortized cost Adjustment to debt measured at fair value June 30, 2021 December 31, 2020 Long-term debt 17,935 64 (15) 17,984 19,794 Short-term debt and current portion of long-term debt 2,225 (2) 2 2,225 2,767 Interest rate and currency derivatives used to manage debt 70 — 17 87 142 Total debt 20,230 62 4 20,296 22,703 Cash and cash equivalents (9,722) — — (9,722) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents (41) — — (41) 74 Net debt (a) 10,467 62 4 10,533 8,862 (a) Net debt does not include lease liabilities, which amounted to €1,489 million as of June 30, 2021 and €1,163 million as of December 31, 2020.
Summary of Debt by Type Valuation of Redemption	The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2021 December 31, 2020 non-current current Total non-current current Total Bond issues 17,897 1,938 19,835 19,698 2,280 21,978 Other bank borrowings 87 133 220 96 200 296 Other borrowings — 2 2 — 2 2 Bank credit balances — 152 152 — 285 285 Interest rate and currency derivatives used to manage debt — 87 87 57 85 142 Total debt 17,984 2,312 20,296 19,851 2,852 22,703 Cash and cash equivalents — (9,722) (9,722) — (13,915) (13,915) Interest rate and currency derivatives used to manage cash and cash equivalents — (41) (41) 6 68 74 Net debt 17,984 (7,451) 10,533 19,857 (10,995) 8,862
Summary of Market Value of Net Debt	The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2021 December 31, 2020 Market value 11,811 10,500 Value on redemption 10,533 8,862

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Financial Instruments [Abstract]
Summary of Operating Currency Hedging Instruments	The table below shows operating currency hedging instruments in place as of June 30, 2021. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2021 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 3,777 (43) 3,777 (43) of which US dollar 1,558 (30) 1,558 (30) of which Chinese yuan renminbi 628 (8) 628 (8) of which Singapore dollar 210 (2) 210 (2) of which Japanese yen 145 (1) 145 (1) of which Mexican peso 89 (2) 89 (2) Forward currency purchases 2,068 28 2,068 28 of which US dollar 1,059 21 1,059 21 of which Singapore dollar 406 6 406 6 of which Pound sterling 61 — 61 — of which Hungarian forint 53 — 53 — of which Chinese yuan renminbi 50 1 50 1 Total 5,845 (15) 5,845 (15)
Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated	The table below shows financial currency hedging instruments in place as of June 30, 2021. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2021 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 5,525 (78) of which US dollar 4,203 (a) (66) 2022 of which Mexican peso 266 (7) 2021 of which Brazilian real 102 (b) (5) 2022 Forward currency purchases 7,984 30 of which US dollar 4,347 (c) (d) 14 2022 of which Singapore dollar 3,018 (e) 12 2022 of which Japanese yen 295 1 2021 Total 13,509 (48) (a) Includes forward sales with a notional amount of $3,615 million expiring in 2021, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2021, the fair value of these forward contracts represented a liability of €57 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (b) Includes forward sales with a notional amount of BRL 600 million expiring in 2022, designated as a hedge of Sanofi’s net investment in Medley Farmaceutica. As of June 30, 2021, the fair value of these forward contracts represented a liability of €7 million; the opposite entry was recognized in Other comprehensive incom e, with the impact on financial income and expense being immaterial. (c) Includes forward purchases with a notional amount of $1,000 million expiring in 2021 and 2022 , designated as a fair value hedge of USD bond issues against fluctuations in the EUR/USD spot rate. As of June 30, 2021, the fair value of these contracts represented a liability of €5 million, with €0.3 million of that amount credited to Other comprehensive income to recognise the hedging cost. (d) Includes currency swaps with a notional amount of $1,000 million, receive 0.22% pay EUR -0.63% expiring in 2022, designated as a cash flow hedge of $1,000 million of bond issues. As of June 30, 2021, the fair value of the swaps was a liability of €13 million. (e) Includes forward purchases with a notional amount of SGD 1,870 million expiring in 2021, design ated as fair value hedges of an equivalent portion of an intra-group loan against fluctuations in the EUR/SGD spot rate. As of June 30, 2021 , the fair value of these contracts represented a liability of €2 million, of which €0.5 million was credited to Other comprehensive income to recognise the hedging cost.
Disclosure of Instruments	The table below shows instruments of this type in place as of June 30, 2021: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2021 2022 2023 2024 2025 and beyond Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized Eonia / receive 0.06% — 2,000 — — — 2,000 16 2,000 16 — — — pay -0.57% / receive capitalized Eonia — 600 — — — 600 3 — — 600 3 1 pay capitalized SOFR USD / receive 1.03% — — — — 422 422 1 422 1 — — — receive capitalized Eonia / pay 1.48% (a) — 42 57 — — 99 (3) 99 (3) — — — Total — 2,642 57 — 422 3,121 17 2,521 14 600 3 1 (a) These interest rate swaps hedge fixed-rate bonds with a nominal of €99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within “Loans, advances and other long-term receivables”.

Liabilities Related to Busine_2

Liabilities Related to Business Combinations and to Non-Controlling Interest (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests	Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2021 are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Other (b) Total (a) Balance at January 1, 2021 104 312 189 605 New transactions — — 17 17 Payments made (7) — (147) (154) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (c) (20) 20 (29) (29) Other movements — — — — Currency translation differences 2 4 2 8 Balance at June 30, 2021 79 336 32 447 Of which: • Current portion 200 • Non-current portion 247 (a) As of January 1, 2021, this comprised a non-current portion of €387 million and a current portion of €218 million. (b) The contingent consideration liability due to True North Therapeutics as a result of Sanofi’s acquisition of Bioverativ was settled in the first half of 2021. (c) Amounts mainly reported within the income statement line item Fair value remeasurement of contingent consideration.

Non-Current Provisions (Tables)

Non-Current Provisions (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Summary of Movements in Non-current Provisions	The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2021 3,497 879 868 1,975 7,219 Increases in provisions and other liabilities 107 87 4 90 288 Provisions utilized (63) (74) (4) (58) (199) Reversals of unutilized provisions (4) (1) (1) (83) (a) (89) Transfers (3) (2) (159) (b) (28) (192) Net interest related to employee benefits, and unwinding of discount 22 1 — 4 27 Currency translation differences 37 13 1 16 67 Actuarial gains and losses on defined-benefit plans (328) — — — (328) Balance at June 30, 2021 3,265 903 709 1,916 6,793 (a) Amounts charged during the first half of 2021 relate mainly to provisions for products, litigation and other liabilities. (b) This movement includes transfers between current and non-current.
Disclosure of Remeasuresment of Net Defined Benefit Liability Asset	Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Actuarial gains/(losses) on plan assets (24) 308 696 Actuarial gains/(losses) on benefit obligations 352 (a) (454) (b) (963) (a) Includes the effects of (i) the change in discount rates (in a range between +0.50% and +0.30%) and (ii) the change in the inflation rate in the United Kingdom (+0.20%) and in the Eurozone (+0.25%) in the first half of 2021. (b) Includes the effects of (i) the change in the discount rate in the United Kingdom and the United States (-0.50%) and (ii) the change in the inflation rate in the United Kingdom (-0.05%) in the first half of 2020.

Other Operating Income And Ex_2

Other Operating Income And Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Other Operating Expenses	Other operating expenses for the first half of 2021 included €643 million of expenses relating to the alliance with Regeneron (versus €525 million in the first half of 2020), as shown in the table below. (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance (521) (341) (727) Additional share of profit paid by Regeneron towards development costs 51 35 75 Reimbursement to Regeneron of selling expenses incurred (116) (176) (349) Total: Monoclonal Antibody Alliance (586) (482) (1,001) Immuno-Oncology Alliance 37 44 89 Other (mainly Zaltrap ® ) (6) (8) (14) Other operating income/(expenses), net related to Regeneron Alliance (555) (446) (926) of which amount presented in Other operating income 88 79 164

Restructuring Costs and Simil_2

Restructuring Costs and Similar Items (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Summary of Restructuring Costs and Similar Items	Restructuring costs and similar items comprise the following: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Employee-related expenses 72 642 690 Charges, gains or losses on assets (a) 65 62 149 Compensation for early termination of contracts (other than contracts of employment) 10 11 40 Decontamination costs — — (2) Other restructuring costs 180 43 187 Total 327 758 1,064 (a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.

Financial Expenses and Income (

Financial Expenses and Income (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Summary of Analysis of Financial Income and Expenses	An analysis of financial expenses and income is set forth below: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Cost of debt (a) (168) (166) (328) Interest income (b) 30 66 103 Cost of net debt (138) (100) (225) Non-operating foreign exchange gains/(losses) 4 2 (6) Unwinding of discounting of provisions (c) (5) (6) (11) Net interest cost related to employee benefits (23) (32) (59) Gains/(losses) on disposals of financial assets 3 — 6 Net interest expense on lease liabilities (15) (19) (38) Other 13 (12) (4) Net financial income/(expenses) (161) (167) (337) comprising: Financial expenses (189) (198) (390) Financial income 28 31 53 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €5 million in the first half of 2021, €58 million in the first half of 2020, and €93 million over the whole of 2020. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €28 million in the first half of 2021, €37 million in the first half of 2020, and €66 million over the whole of 2020. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).

Income Tax Expense (Tables)

Income Tax Expense (Tables)	6 Months Ended
	Jun. 30, 2021
Income Taxes [Abstract]
Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes	The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Current taxes (806) (1,127) (1,912) Deferred taxes 124 133 99 Total (682) (994) (1,813) Income before tax and investments accounted for using the equity method 3,452 9,941 13,804
Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate	The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2021 (6 months) (a) June 30, 2020 (6 months) (a) December 31, 2020 (12 months) Standard tax rate applicable in France 28.4 32.0 32.0 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (10.1) (20.2) (18.2) Revisions to tax exposures and settlements of tax disputes 1.0 0.2 0.5 Fair value remeasurement of contingent consideration liabilities 0.2 (0.1) — Other (c) 0.3 (1.9) (1.2) Effective tax rate 19.8 10.0 13.1 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For 2020, this line includes the difference between the standard French tax rate and the tax rate applicable to the gain on divestment of Regeneron shares. (c) In determining the amount of the deferred tax liability for 2020, Sanofi look into account changes in the ownership structure of certain subsidiaries.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Operating Segments [Abstract]
Summary of Net Sales by Segment and Geographical Area	The table below sets forth net sales for the six months ended June 30, 2021 and June 30, 2020: (€ million) Europe United States Other countries June 30, 2021 Europe United States Other countries June 30, 2020 Pharmaceuticals 3,575 4,892 4,729 13,196 3,347 4,806 4,867 13,020 General Medicines 2,228 1,262 3,728 7,218 2,232 1,458 3,928 7,618 of which Lantus ® 246 429 614 1,289 281 474 662 1,417 Toujeo ® 195 120 185 500 188 143 165 496 Praluent ® 75 5 24 104 56 68 22 146 Multaq ® 12 132 7 151 12 135 7 154 Lovenox ® 368 15 385 768 298 15 317 630 Plavix ® (1) 60 5 420 485 66 4 438 508 Generics (1) 4 70 320 394 5 75 341 421 Specialty Care 1,347 3,630 1,001 5,978 1,115 3,348 939 5,402 of which Aubagio ® 264 666 64 994 231 775 62 1,068 Cerezyme ® 124 83 136 343 125 90 153 368 Myozyme/Lumizyme ® 200 180 103 483 193 178 101 472 Fabrazyme ® 111 190 111 412 98 206 109 413 Eloctate ® — 216 62 278 — 234 96 330 Jevtana ® 75 119 46 240 92 123 56 271 Dupixent ® 289 1,740 261 2,290 174 1,310 150 1,634 Vaccines 244 626 1,067 1,937 281 491 1,064 1,836 of which Polio/Pertussis/Hib vaccines 145 241 667 1,053 162 183 714 1,059 Influenza vaccines 18 — 178 196 5 13 161 179 Consumer Healthcare (2) 653 570 979 2,202 717 583 1,024 2,324 of which Allergy 34 200 109 343 36 214 131 381 Pain Care 250 91 187 528 244 98 207 549 Digestive Wellness 200 61 312 573 192 36 263 491 Total net sales 4,472 6,088 6,775 17,335 4,345 5,880 6,955 17,180 (1) Sanofi has altered the presentation of net third-party sales by franchise at the level of the General Medicines GBU. Industrial sales (primarily of active ingredients and semi-finished products) to third parties such as CMOs are now grouped together separately. Previously, such sales were presented within the Diabetes franchise and the Cardiovascular & Established Prescription Products franchises, on the line for the relevant product. (2) For the Consumer Healthcare GBU, Sanofi has adopted a more granular presentation by introducing new sub-categories that reflect consumer trends and the strengths and opportunities of the portfolio.
Schedule of Segment Results	Segment results are shown in the table below: June 30, 2021 (6 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 13,196 1,937 2,202 — 17,335 Other revenues 108 461 27 — 596 Cost of sales (3,403) (1,254) (753) (131) (5,541) Research and development expenses (2,041) (316) (69) (237) (2,663) Selling and general expenses (2,480) (359) (700) (991) (4,530) Other operating income and expenses (466) 121 23 22 (300) Share of profit/(loss) from investments accounted for using the equity method 13 8 5 — 26 Net income attributable to non-controlling interests (16) — (4) — (20) Business operating income 4,911 598 731 (1,337) 4,903 June 30, 2020 (6 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 13,020 1,836 2,324 — 17,180 Other revenues 70 474 30 — 574 Cost of sales (3,406) (1,176) (781) (144) (5,507) Research and development expenses (2,065) (319) (69) (239) (2,692) Selling and general expenses (2,388) (369) (744) (1,106) (4,607) Other operating income and expenses (150) 4 21 (130) (255) Share of profit/(loss) from investments accounted for using the equity method 4 — 7 — 11 Net income attributable to non-controlling interests (17) — (4) — (21) Business operating income (a) 5,068 450 784 (1,619) 4,683 (a) 2020 figures have been adjusted to take account of the reallocation of certain expenses (in particular IT costs related to Sanofi’s new digital organization) from the Pharmaceuticals, Vaccines and Consumer Healthcare operating segments to the “Other” segment. December 31, 2020 (12 months) (€ million) Pharmaceuticals Vaccines Consumer Healthcare Other Total Net sales 25,674 5,973 4,394 — 36,041 Other revenues 128 1,141 59 — 1,328 Cost of sales (6,980) (3,312) (1,528) (284) (12,104) Research and development expenses (4,170) (682) (153) (524) (5,529) Selling and general expenses (4,926) (789) (1,419) (2,256) (9,390) Other operating income and expenses (490) 4 53 (129) (562) Share of profit/(loss) from investments accounted for using the equity method 5 2 9 — 16 Net income attributable to non-controlling interests (33) — (5) — (38) Business operating income (a) 9,208 2,337 1,410 (3,193) 9,762 (a) 2020 figures have been adjusted to take account of the reallocation of certain expenses (in particular IT costs related to Sanofi’s new digital organization) from the Pharmaceuticals, Vaccines and Consumer Healthcare operating segments to the “Other” segment.
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method	The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method: (€ million) June 30, 2021 (6 months) June 30, 2020 (6 months) December 31, 2020 (12 months) Business operating income 4,903 4,683 9,762 Share of profit/(loss) from investments accounted for using the equity method (a) (26) (11) (16) Net income attributable to non-controlling interests (b) 20 21 38 Amortization and impairment of intangible assets (953) (1,206) (2,011) Fair value remeasurement of contingent consideration (4) 54 124 Expenses arising from the impact of acquisitions on inventories — (36) (53) Restructuring costs and similar items (327) (758) (1,064) Other gains and losses, and litigation (c) — 136 136 Gain on divestment of Regeneron shares on May 29, 2020 (d) — 7,225 7,225 Operating income 3,613 10,108 14,141 Financial expenses (189) (198) (390) Financial income 28 31 53 Income before tax and investments accounted for using the equity method 3,452 9,941 13,804 (a) Excludes (i) restructuring costs and (ii) expenses arising from the impact of acquisitions on investments accounted for using the equity method. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) For 2020, this line mainly comprises the gain on the sale of operations related to the Seprafilm ® product to Baxter. (d) For 2020, this line includes the gain on the sale of (i) 13 million shares of Regeneron common stock in the registered public offering and (ii) the 9.8 million shares repurchased by Regeneron, but does not include the gain arising from the remeasurement of the 400,000 retained shares at market value of May 29, 2020.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment	Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2021 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 144 70 — 214 Acquisitions of property, plant and equipment 445 196 27 668 Acquisitions of other intangible assets 263 81 6 350 June 30, 2020 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 149 44 3 196 Acquisitions of property, plant and equipment 294 181 27 502 Acquisitions of other intangible assets 153 21 6 180 December 31, 2020 (€ million) Pharmaceuticals Vaccines Consumer Healthcare Total Investments accounted for using the equity method 154 47 — 201 Acquisitions of property, plant and equipment 755 404 95 1,254 Acquisitions of other intangible assets 532 322 6 860
Summary of Geographical Information on Net Sales and Non-Current Assets	In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2021 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,335 4,472 1,087 6,388 6,088 6,475 Non-current assets: • property, plant and equipment 9,503 5,874 3,162 2,699 1,996 930 • goodwill 44,979 — — — — — • other intangible assets 19,466 7,272 — 10,895 — 1,299 June 30, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 17,180 4,345 1,061 6,151 5,880 6,684 Non-current assets: • property, plant and equipment 9,368 5,683 3,067 2,756 2,153 929 • goodwill 45,254 — — — — — • other intangible assets 17,021 6,544 — 8,838 — 1,639 December 31, 2020 (€ million) Total Europe of which France North of which United States Other countries Net sales 36,041 9,151 2,223 14,060 13,465 12,830 Non-current assets: • property, plant and equipment 9,365 5,895 3,189 2,542 1,899 928 • goodwill 44,364 — — — — — • other intangible assets 18,421 6,278 — 10,675 — 1,468

Basis of Preparation of the H_4

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details)	Jun. 30, 2021
Lebanon
Disclosure of initial application of standards or interpretations [line items]
Cumulative consumer price inflation rate	100.00%
Argentina
Disclosure of initial application of standards or interpretations [line items]
Cumulative consumer price inflation rate	100.00%

Main Acquisitions of the Peri_2

Main Acquisitions of the Period (Details) € / shares in Units, € in Millions, $ in Millions		Apr. 29, 2021EUR (€)	Apr. 16, 2021	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2020EUR (€)	Apr. 09, 2021EUR (€)	Apr. 09, 2021USD ($)	Apr. 08, 2021EUR (€)	Apr. 08, 2021USD ($)	Nov. 02, 2020€ / sharesshares
Disclosure of detailed information about business combination [line items]
Net cash flow on acquisition	[1]			€ 1,520	€ 2,360	€ 5,336
Kymab
Disclosure of detailed information about business combination [line items]
Cash transferred									€ 973	$ 1,100
Commitments related to potential milestone payments for projects under collaboration agreements | $										$ 350
Other intangible assets recognized at acquisition date									€ 956
Net cash flow on acquisition				922
Kiadis
Disclosure of detailed information about business combination [line items]
Other intangible assets recognized at acquisition date		€ 333
Net cash flow on acquisition				319
Number of shares included in public offer | shares											61,084,776
Purchase price (in euros per share) | € / shares											€ 5.45
Proportion of issued and outstanding share capital tendered			95.03%
Equity interest acquired		97.39%
Proportion of ownership interest in subsidiary to be held after statutory public buy-out procedure		100.00%
Tidal Therapeutics
Disclosure of detailed information about business combination [line items]
Cash transferred							€ 136	$ 160
Commitments related to potential milestone payments for projects under collaboration agreements | $								$ 310
Other intangible assets recognized at acquisition date							€ 130
Net cash flow on acquisition				€ 135
[1]	This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations.For the six months ended June 30, 2021, it includes the net cash outflow arising from the acquisitions of Kymab, Kiadis and Tidal (see Note B.1.).

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (€) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	€ 523	€ 1,310
Capitalized interest	6	11
Pharmaceuticals
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	356	831
Pharmaceuticals | Industrial facilities
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	232	634
Pharmaceuticals | Research sites
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	72	152
Pharmaceuticals | Other
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	52	45
Vaccines
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	140	384
Consumer Healthcare
Disclosure of acquisitions of property plant and equipment by operating segments [Line Items]
Acquisitions	€ 27	€ 95

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) € in Millions	1 Months Ended	6 Months Ended
	Dec. 31, 2018lease	Jun. 30, 2021EUR (€)	Dec. 31, 2020EUR (€)
Disclosure of detailed information about investment property [line items]
Firm orders of property, plant and equipment		€ 764
Property, plant and equipment leased - right-of-use assets		1,473	€ 1,198
Lease liability		1,489	€ 1,163
Cambridge, Massachusetts
Disclosure of detailed information about investment property [line items]
Number of lease agreements signed | lease	2
Initial lease term	15 years
Office space, Cambridge, Massachusetts
Disclosure of detailed information about investment property [line items]
Property, plant and equipment leased - right-of-use assets		313
Laboratory facilities, Cambridge, Massachusetts
Disclosure of detailed information about investment property [line items]
Lease liability		€ 479

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details) € in Millions	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	€ 18,421
Other intangible assets, ending balance	19,466
Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	72,422
Changes in scope of consolidation	1,419
Acquisitions and other increases	414
Disposals and other decreases	(81)
Currency translation differences	1,044
Transfers	(2)
Other intangible assets, ending balance	75,216
Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	(54,001)
Acquisitions and other increases	(868)
Disposals and other decreases	50
Currency translation differences	(753)
Impairment losses, net of reversals	(178)
Other intangible assets, ending balance	(55,750)
Acquired R&D
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	6,092
Other intangible assets, ending balance	7,742
Acquired R&D | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	9,600
Changes in scope of consolidation	1,337
Acquisitions and other increases	277
Disposals and other decreases	0
Currency translation differences	229
Transfers	(7)
Other intangible assets, ending balance	11,436
Acquired R&D | Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	(3,508)
Acquisitions and other increases	0
Disposals and other decreases	1
Currency translation differences	(50)
Impairment losses, net of reversals	(137)
Other intangible assets, ending balance	(3,694)
Products, trademarks and other rights
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	11,729
Other intangible assets, ending balance	11,125
Products, trademarks and other rights | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	61,074
Changes in scope of consolidation	82
Acquisitions and other increases	63
Disposals and other decreases	(68)
Currency translation differences	803
Transfers	10
Other intangible assets, ending balance	61,964
Products, trademarks and other rights | Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	(49,345)
Acquisitions and other increases	(797)
Disposals and other decreases	37
Currency translation differences	(693)
Impairment losses, net of reversals	(41)
Other intangible assets, ending balance	(50,839)
Software
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	600
Other intangible assets, ending balance	599
Software | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	1,748
Changes in scope of consolidation	0
Acquisitions and other increases	74
Disposals and other decreases	(13)
Currency translation differences	12
Transfers	(5)
Other intangible assets, ending balance	1,816
Software | Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance	(1,148)
Acquisitions and other increases	(71)
Disposals and other decreases	12
Currency translation differences	(10)
Impairment losses, net of reversals	0
Other intangible assets, ending balance	€ (1,217)

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	€ 44,979	€ 44,364
Carrying amount of intangible assets	19,466	18,421
Other intangible assets excluding software
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases	340
Marketed products
Disclosure of reconciliation of changes in goodwill [line items]
Carrying amount of intangible assets	€ 10,500	11,400
Weighted average amortization period	10 years
Technological platforms
Disclosure of reconciliation of changes in goodwill [line items]
Carrying amount of intangible assets	€ 400	200
Weighted average amortization period	13 years
Trademarks
Disclosure of reconciliation of changes in goodwill [line items]
Carrying amount of intangible assets	€ 100	€ 100
Weighted average amortization period	12 years

Impairment of Intangible Asse_2

Impairment of Intangible Assets (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Impairment Of Assets [Abstract]
Impairment loss on other intangible assets	€ 178	€ 323	€ 330

Investments Accounted for Usi_3

Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of transactions between related parties [Line Items]
Investments in joint ventures	€ 214	€ 201
MSP Vaccine Company | MCM Vaccine BV
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture	100.00%
Infraserv GmbH & Co. Höchst KG
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture	31.20%
Investments in joint ventures	€ 69	72
MSP Vaccine Company
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture	50.00%
Investments in joint ventures	€ 67	44
Other investments
Disclosure of transactions between related parties [Line Items]
Proportion of voting rights held in joint venture	0.00%
Investments in joint ventures	€ 78	€ 85

Investments Accounted for Usi_4

Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - Associates and joint ventures - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of transactions between related parties [Line Items]
Sales	€ 31	€ 52	€ 75
Royalties and other income	26	65	97
Accounts receivable and other receivables	66	7	50
Purchases and other expenses (including research expenses)	124	605	747
Accounts payable and other payables	€ 17	€ 5	€ 15

Other Non-Current Assets - Summ

Other Non-Current Assets - Summary of Other Non-current Assets (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Other Non Current Assets [Line Items]
Other financial assets at fair value through profit or loss	€ 836	€ 890
Pre-funded pension obligations	179	177
Long-term prepaid expenses	77	92
Long-term loans and advances and other non-current receivables	508	537
Derivative financial instruments	21	24
Total	2,699	2,734
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Equity instruments or debt instruments at fair value through other comprehensive income	669	588
Debt securities
Disclosure Of Other Non Current Assets [Line Items]
Equity instruments or debt instruments at fair value through other comprehensive income	€ 409	€ 426

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ 6,802	€ 7,491
Gross value
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	6,932	7,633
Allowances
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ 130	€ 142

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables	€ 2	€ 40
Derecognized receivables	€ 522		€ 18

Accounts Receivable - Summary_2

Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 427	€ 549
Less than 1 month
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	78	271
1 to 3 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	105	97
3 to 6 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	96	52
6 to 12 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	33	34
Greater than 12 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 115	€ 95

Consolidated Shareholders' Eq_3

Consolidated Shareholders' Equity - Additional Information (Details) - EUR (€)	Apr. 30, 2021	Apr. 28, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 25, 2021	Feb. 04, 2021	Dec. 31, 2020	Jun. 26, 2020	Feb. 05, 2020
Disclosure of classes of share capital [Line Items]
Share capital			€ 2,521,571,560
Number of shares (in shares)			1,260,785,780
Par value per share (in euros per share)			€ 2
Number of stock option not taken for computing diluted earning per share (in shares)			600,000	700,000			600,000
Employees share ownership plan
Disclosure of classes of share capital [Line Items]
Subscription price (in euros per share)						€ 69.38			€ 70.67
Number of shares subscribed (in shares)					2,438,590			2,467,101
Number of shares issued immediately for employer's contribution (in shares)					124,112			123,615
Expense recognized			€ 51,000,000	€ 52,000,000
Share Repurchase 2021 Program
Disclosure of classes of share capital [Line Items]
Period of share repurchase program	18 months
Share Repurchase 2020 Program
Disclosure of classes of share capital [Line Items]
Period of share repurchase program		18 months
Number of shares repurchased (in shares)			1,758,569
Amount of shares repurchased			€ 140,000,000
Share capital | Sanofi
Disclosure of classes of share capital [Line Items]
Capital increase by exercise of stock subscription options (in shares)			62,396
Capital increase by issuance of restricted shares (in shares)			1,751,646

Consolidated Shareholders' Eq_4

Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details) - shares shares in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Jan. 01, 2020
Share Capital, Reserves And Other Equity Interest [Abstract]
Number of shares (in shares)	8,250	8,280	2,590	20
% of share capital for the period	0.655%	0.658%	0.207%	0.002%

Consolidated Shareholders' Eq_5

Consolidated Shareholders' Equity - Principal Characteristics of Restricted Share Plans (Details) - Restricted share plan 2021 € / shares in Units, € in Millions	6 Months Ended
	Jun. 30, 2021EUR (€)shares€ / shares
Disclosure of classes of share capital [Line Items]
Service period	3 years
Total number of shares awarded (in shares)	3,484,420
Fair value of plan at the date of grant | €	€ 262
Without market condition
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	2,209,901
Fair value per share awarded (in euros per share) | € / shares	€ 77.27
With market condition
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	1,274,519
Fair value per share awarded (in euros per share) | € / shares	€ 71.30

Consolidated Shareholders' Eq_6

Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Restricted shares
Disclosure of classes of share capital [Line Items]
Total expense for restricted share plans	€ 83	€ 113
Number of shares not yet fully vested (in shares)	9,996,495	10,900,815
Restricted share plan 2021
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,484,420	0
Restricted share plan 2020
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,175,084	3,340,501
Restricted share plan 2019
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,252,099	3,545,507
Restricted share plan 2018
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	84,892	4,014,807

Consolidated Shareholders' Eq_7

Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan	6 Months Ended
	Jun. 30, 2021shares€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) | shares	2,465,648
Exercisable, number of options (in shares) | shares	2,076,864
From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) | shares	163,367
Weighted average residual life (years)	8 months 4 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 56.44
Exercisable, number of options (in shares) | shares	163,367
Weighted average exercise price per share, options exercisable (in euros per share)	€ 56.44
From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) | shares	168,784
Weighted average residual life (years)	6 years 10 months 6 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 65.84
Exercisable, number of options (in shares) | shares	0
Weighted average exercise price per share, options exercisable (in euros per share)	€ 0
From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) | shares	1,499,313
Weighted average residual life (years)	3 years 7 months 6 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 74.10
Exercisable, number of options (in shares) | shares	1,279,313
Weighted average exercise price per share, options exercisable (in euros per share)	€ 73.65
From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) | shares	634,184
Weighted average residual life (years)	4 years 10 months 9 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 89.19
Exercisable, number of options (in shares) | shares	634,184
Weighted average exercise price per share, options exercisable (in euros per share)	€ 89.19
Bottom of range | From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	50
Bottom of range | From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Bottom of range | From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Bottom of range | From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range | From €50.00 to €60.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Top of range | From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Top of range | From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range | From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	€ 90

Consolidated Shareholders' Eq_8

Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share Capital, Reserves And Other Equity Interest [Abstract]
Average number of shares outstanding (in shares)	1,250.3	1,251.7	1,253.6
Adjustment for stock options with dilutive effect (in shares)	0.3	0.4	0.4
Adjustment for restricted shares (in shares)	5	6.1	6.1
Average number of shares used to compute diluted earnings per share (in shares)	1,255.6	1,258.2	1,260.1

Consolidated Shareholders' Eq_9

Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of analysis of other comprehensive income by item [Line Items]
Items not subsequently reclassifiable to profit or loss	€ 380	€ 64	€ 12
Items subsequently reclassifiable to profit or loss	1,074	(902)	(4,022)
Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Items subsequently reclassifiable to profit or loss	4		1
Items subsequently reclassifiable to profit or loss | Debt instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Items subsequently reclassifiable to profit or loss	4		5
Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Actuarial gains/(losses) excluding investments accounted for using the equity method	328	(146)	(267)
Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes	0	0	(1)
Tax effects	(11)	(19)	45
Items not subsequently reclassifiable to profit or loss	380	64	12
Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	70	365	358
Change in fair value (investments accounted for using the equity method, net of taxes)	0	(13)	(14)
Equity risk hedging instruments designated as fair value hedges	(3)	(53)	(24)
Tax effects	(4)	(70)	(85)
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	(4)	29	4
Change in fair value (investments accounted for using the equity method, net of taxes)	0	0	0
Tax effects	0	(9)	(2)
Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)	1,171	(590)	(3,872)
Currency translation differences	(3)	24	32
Hedges of net investments in foreign operations	(107)	(60)	180
Tax effects	30	19	(58)
Items subsequently reclassifiable to profit or loss	1,074	(902)	(4,022)
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	(17)	4	15
Change in fair value (investments accounted for using the equity method, net of taxes)	0	0	0
Tax effects	4	(1)	(3)
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Regeneron
Disclosure of analysis of other comprehensive income by item [Line Items]
Currency translation differences	€ 0	€ (318)	€ (318)

Debt, Cash and Cash Equivalen_3

Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Financial Instruments [Abstract]
Long-term debt	€ 17,935	€ 19,745
Short-term debt and current portion of long-term debt	2,225	2,767
Interest rate and currency derivatives used to manage debt	70	119
Total debt	20,230	22,631
Cash and cash equivalents	(9,722)	(13,915)	€ (15,969)	€ (9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	74
Net debt	10,467	8,790
Current and non-current lease liabilities	€ 1,489	€ 1,163

Debt, Cash and Cash Equivalen_4

Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	€ 17,935	€ 19,745
Short-term debt and current portion of long-term debt	2,225	2,767
Interest rate and currency derivatives used to manage debt	70	119
Total debt	20,230	22,631
Cash and cash equivalents	(9,722)	(13,915)	€ (15,969)	€ (9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	74
Net debt	10,467	8,790
Current and non-current lease liabilities	1,489	1,163
Amortized cost
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	64
Short-term debt and current portion of long-term debt	(2)
Interest rate and currency derivatives used to manage debt	0
Total debt	62
Cash and cash equivalents	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0
Net debt	62
Adjustment to debt measured at fair value
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	(15)
Short-term debt and current portion of long-term debt	2
Interest rate and currency derivatives used to manage debt	17
Total debt	4
Cash and cash equivalents	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0
Net debt	4
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt	17,984	19,794
Short-term debt and current portion of long-term debt	2,225	2,767
Interest rate and currency derivatives used to manage debt	87	142
Total debt	20,296	22,703
Cash and cash equivalents	(9,722)	(13,915)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	74
Net debt	€ 10,533	€ 8,862

Debt, Cash and Cash Equivalen_5

Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (€) € in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Interest rate and currency derivatives used to manage debt	€ 70	€ 119
Total debt	20,230	22,631
Cash and cash equivalents	(9,722)	(13,915)	€ (15,969)	€ (9,427)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	74
Net debt	10,467	8,790
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	19,835	21,978
Other bank borrowings	220	296
Other borrowings	2	2
Bank credit balances	152	285
Interest rate and currency derivatives used to manage debt	87	142
Total debt	20,296	22,703
Cash and cash equivalents	(9,722)	(13,915)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	74
Net debt	10,533	8,862
Value on redemption | non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents	0	0
Interest rate and currency derivatives used to manage cash and cash equivalents	0	6
Net debt	17,984	19,857
Value on redemption | current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents	(9,722)	(13,915)
Interest rate and currency derivatives used to manage cash and cash equivalents	(41)	68
Net debt	(7,451)	(10,995)
Value on redemption | non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	17,897	19,698
Other bank borrowings	87	96
Other borrowings	0	0
Bank credit balances	0	0
Interest rate and currency derivatives used to manage debt	0	57
Total debt	17,984	19,851
Value on redemption | current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues	1,938	2,280
Other bank borrowings	133	200
Other borrowings	2	2
Bank credit balances	152	285
Interest rate and currency derivatives used to manage debt	87	85
Total debt	€ 2,312	€ 2,852

Debt, Cash and Cash Equivalen_6

Debt, Cash and Cash Equivalents - Additional Information (Details) € in Millions, $ in Billions	Jun. 30, 2021EUR (€)extension	Jun. 30, 2021USD ($)bond	Jun. 30, 2021USD ($)extension	Sep. 30, 2015EUR (€)	Mar. 31, 2011EUR (€)
Disclosure of detailed information about borrowings [Line Items]
Number of bond issues redeemed | bond		2
€2 billion bonds, maturating March 2021
Disclosure of detailed information about borrowings [Line Items]
Notional amount					€ 2,000
€500 million bonds, maturating September 2025
Disclosure of detailed information about borrowings [Line Items]
Notional amount				€ 500
Syndicated credit facility, expires in 2022
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 4,000
Credit facilities, extension option	1 year
Syndicated credit facility, expires in 2025
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 4,000
Credit facilities, extension option	1 year
Credit facilities, number of extension options | extension	2		2
Commercial paper program in France
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs	€ 6,000
Commercial paper program in USA
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs | $			$ 10
Average drawdown | $		$ 1.2

Debt, Cash and Cash Equivalen_7

Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details) - EUR (€) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about borrowings [Line Items]
Market value	€ 20,230	€ 22,631
Market value
Disclosure of detailed information about borrowings [Line Items]
Market value	11,811	10,500
Value on redemption
Disclosure of detailed information about borrowings [Line Items]
Market value	20,296	22,703
Value on redemption	€ 10,533	€ 8,862

Derivative Financial Instrume_3

Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details) € in Millions	Jun. 30, 2021EUR (€)
Notional amount
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 5,845
Notional amount | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,777
Notional amount | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,558
Notional amount | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	628
Notional amount | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	210
Notional amount | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	145
Notional amount | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	89
Notional amount | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,068
Notional amount | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,059
Notional amount | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	406
Notional amount | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	61
Notional amount | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	53
Notional amount | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	50
Notional amount | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Notional amount | Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	5,845
Notional amount | Not eligible for hedge accounting | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,777
Notional amount | Not eligible for hedge accounting | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,558
Notional amount | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	628
Notional amount | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	210
Notional amount | Not eligible for hedge accounting | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	145
Notional amount | Not eligible for hedge accounting | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	89
Notional amount | Not eligible for hedge accounting | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,068
Notional amount | Not eligible for hedge accounting | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,059
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	406
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	61
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	53
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	50
Fair value
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(15)
Fair value | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(43)
Fair value | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(30)
Fair value | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(8)
Fair value | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(2)
Fair value | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(2)
Fair value | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	28
Fair value | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	21
Fair value | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	6
Fair value | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Fair value | Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(15)
Fair value | Not eligible for hedge accounting | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(43)
Fair value | Not eligible for hedge accounting | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(30)
Fair value | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(8)
Fair value | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(2)
Fair value | Not eligible for hedge accounting | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value | Not eligible for hedge accounting | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(2)
Fair value | Not eligible for hedge accounting | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	28
Fair value | Not eligible for hedge accounting | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	21
Fair value | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	6
Fair value | Not eligible for hedge accounting | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value | Not eligible for hedge accounting | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Value of hedge recognized in equity | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency sales in Mexican Peso
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Pound Sterling
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Hungarian Forint
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place
Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place

Derivative Financial Instrume_4

Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details) € in Millions, R$ in Millions, $ in Millions, $ in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2020EUR (€)	Jun. 30, 2021USD ($)	Jun. 30, 2021BRL (R$)	Jun. 30, 2021SGD ($)
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Gain (losses) on cash flow hedges, recognized in other comprehensive income	€ 4	€ (29)	€ (4)
Forward currency sales in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Derivative financial liabilities	57
Forward currency sales in US Dollar | Bioverativ
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount | $				$ 3,615
Forward currency sales in Brazilian Real
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Derivative financial liabilities	7
Forward currency sales in Brazilian Real | Medley Farmaceutica
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount | R$					R$ 600
Forward currency purchases in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount | $				1,000
Derivative financial liabilities	5
Gain (losses) on cash flow hedges, recognized in other comprehensive income	0.3
Forward currency purchases in Singapore Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount | $						$ 1,870
Derivative financial liabilities	2
Gain (losses) on cash flow hedges, recognized in other comprehensive income	0.5
Currency swaps in USD to EUR
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount | $				$ 1,000
Derivative financial liabilities	€ 13
Currency swaps, percentage received	0.22%			0.22%	0.22%	0.22%
Currency swaps, percentage paid	0.63%			0.63%	0.63%	0.63%
Notional amount
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	€ 13,509
Notional amount | Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	5,525
Notional amount | Forward currency sales in US Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	4,203
Notional amount | Forward currency sales in Mexican Peso | 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	266
Notional amount | Forward currency sales in Brazilian Real | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	102
Notional amount | Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	7,984
Notional amount | Forward currency purchases in US Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	4,347
Notional amount | Forward currency purchases in Singapore Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	3,018
Notional amount | Forward currency purchases in Japanese Yen | 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	295
Fair value
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(48)
Fair value | Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(78)
Fair value | Forward currency sales in US Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(66)
Fair value | Forward currency sales in Mexican Peso | 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(7)
Fair value | Forward currency sales in Brazilian Real | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(5)
Fair value | Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	30
Fair value | Forward currency purchases in US Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	14
Fair value | Forward currency purchases in Singapore Dollar | 2022
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	12
Fair value | Forward currency purchases in Japanese Yen | 2021
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	€ 1

Derivative Financial Instrume_5

Derivative Financial Instruments - Disclosure of Instruments (Details) € in Millions	Jun. 30, 2021EUR (€)
Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 3,121
Nominal value of interest rate swaps hedge fixed-rate bonds	5,845
Notional amount | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,521
Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	600
Nominal value of interest rate swaps hedge fixed-rate bonds
Notional amount | 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Notional amount | 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,642
Notional amount | 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	57
Notional amount | 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Notional amount | 2025 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	422
Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	17
Nominal value of interest rate swaps hedge fixed-rate bonds	(15)
Fair value | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	14
Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3
Nominal value of interest rate swaps hedge fixed-rate bonds
Value of hedge recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	1
Nominal value of interest rate swaps hedge fixed-rate bonds
pay capitalized Eonia / receive 0.06%
Disclosure of detailed information about financial instruments [line items]
Interest rate	0.06%
pay capitalized Eonia / receive 0.06% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 2,000
pay capitalized Eonia / receive 0.06% | Notional amount | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,000
pay capitalized Eonia / receive 0.06% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Notional amount | 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Notional amount | 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,000
pay capitalized Eonia / receive 0.06% | Notional amount | 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Notional amount | 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Notional amount | 2025 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	16
pay capitalized Eonia / receive 0.06% | Fair value | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	16
pay capitalized Eonia / receive 0.06% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Eonia / receive 0.06% | Value of hedge recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
pay -0.57% / receive capitalized Eonia
Disclosure of detailed information about financial instruments [line items]
Interest rate	(0.57%)
pay -0.57% / receive capitalized Eonia | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 600
pay -0.57% / receive capitalized Eonia | Notional amount | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	600
pay -0.57% / receive capitalized Eonia | Notional amount | 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Notional amount | 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	600
pay -0.57% / receive capitalized Eonia | Notional amount | 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Notional amount | 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Notional amount | 2025 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3
pay -0.57% / receive capitalized Eonia | Fair value | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay -0.57% / receive capitalized Eonia | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3
pay -0.57% / receive capitalized Eonia | Value of hedge recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 1
pay capitalized SOFR USD / receive 1.03%
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.03%
pay capitalized SOFR USD / receive 1.03% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 422
pay capitalized SOFR USD / receive 1.03% | Notional amount | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	422
pay capitalized SOFR USD / receive 1.03% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Notional amount | 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Notional amount | 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Notional amount | 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Notional amount | 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Notional amount | 2025 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	422
pay capitalized SOFR USD / receive 1.03% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	1
pay capitalized SOFR USD / receive 1.03% | Fair value | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	1
pay capitalized SOFR USD / receive 1.03% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.03% | Value of hedge recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
receive capitalized Eonia / pay 1.48%
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.48%
receive capitalized Eonia / pay 1.48% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 99
Nominal value of interest rate swaps hedge fixed-rate bonds	99
receive capitalized Eonia / pay 1.48% | Notional amount | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	99
receive capitalized Eonia / pay 1.48% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
receive capitalized Eonia / pay 1.48% | Notional amount | 2021
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
receive capitalized Eonia / pay 1.48% | Notional amount | 2022
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	42
receive capitalized Eonia / pay 1.48% | Notional amount | 2023
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	57
receive capitalized Eonia / pay 1.48% | Notional amount | 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
receive capitalized Eonia / pay 1.48% | Notional amount | 2025 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
receive capitalized Eonia / pay 1.48% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(3)
receive capitalized Eonia / pay 1.48% | Fair value | Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(3)
receive capitalized Eonia / pay 1.48% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
receive capitalized Eonia / pay 1.48% | Value of hedge recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0

Derivative Financial Instrume_6

Derivative Financial Instruments - Additional Information (Details) - Equity derivatives - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2021
Disclosure of detailed information about financial instruments [line items]
Shares in derivative instrument (in shares)	593,712
Financial instruments designated as fair value hedges		€ 29

Liabilities Related to Busine_3

Liabilities Related to Business Combinations and to Non-Controlling Interest - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	€ 605
New transactions	17
Payments made	(154)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	(29)
Other movements	0
Currency translation differences	8
Ending balance	447
Current portion	200	€ 218
Non-current portion	247	€ 387
Bayer contingent consideration arising from the acquisition of Genzyme
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	104
New transactions	0
Payments made	(7)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	(20)
Other movements	0
Currency translation differences	2
Ending balance	79
MSD contingent consideration (European Vaccines business)
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	312
New transactions	0
Payments made	0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	20
Other movements	0
Currency translation differences	4
Ending balance	336
Other
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	189
New transactions	17
Payments made	(147)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	(29)
Other movements	0
Currency translation differences	2
Ending balance	€ 32

Liabilities Related to Busine_4

Liabilities Related to Business Combinations and to Non-Controlling Interest - Additional Information (Details) € in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)	Dec. 31, 2020EUR (€)
MSD contingent consideration (European Vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Increase in fair value of liability		2.00%
Disclosure of liabilities related to business combinations and to noncontrolling interests		€ 336	€ 312
Bayer
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Payment to sale of business period	10 years
Fair value of the contingent consideration payable to Bayer		€ 79	€ 104
Increase in fair value of liability		1.00%
Bayer | Top of range
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Potentiel payments related to percentage of sales of alemtuzumab | $	$ 1,250

Non-Current Provisions - Summar

Non-Current Provisions - Summary of Movements in Non-current Provisions (Details) € in Millions	6 Months Ended
	Jun. 30, 2021EUR (€)
Reconciliation of changes in other provisions [abstract]
Beginning balance	€ 7,219
Increases in provisions and other liabilities	288
Provisions utilized	(199)
Reversals of unutilized provisions	(89)
Transfers	(192)
Net interest related to employee benefits, and unwinding of discount	27
Currency translation differences	67
Actuarial gains and losses on defined-benefit plans	(328)
Ending balance	6,793
Provisions for pensions & other post-employment benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	3,497
Increases in provisions and other liabilities	107
Provisions utilized	(63)
Reversals of unutilized provisions	(4)
Transfers	(3)
Net interest related to employee benefits, and unwinding of discount	22
Currency translation differences	37
Actuarial gains and losses on defined-benefit plans	(328)
Ending balance	3,265
Provisions for other long-term benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	879
Increases in provisions and other liabilities	87
Provisions utilized	(74)
Reversals of unutilized provisions	(1)
Transfers	(2)
Net interest related to employee benefits, and unwinding of discount	1
Currency translation differences	13
Actuarial gains and losses on defined-benefit plans	0
Ending balance	903
Restructuring provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	868
Increases in provisions and other liabilities	4
Provisions utilized	(4)
Reversals of unutilized provisions	(1)
Transfers	(159)
Net interest related to employee benefits, and unwinding of discount	0
Currency translation differences	1
Actuarial gains and losses on defined-benefit plans	0
Ending balance	709
Other provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	1,975
Increases in provisions and other liabilities	90
Provisions utilized	(58)
Reversals of unutilized provisions	(83)
Transfers	(28)
Net interest related to employee benefits, and unwinding of discount	4
Currency translation differences	16
Actuarial gains and losses on defined-benefit plans	0
Ending balance	€ 1,916

Non-Current Provisions - Provis

Non-Current Provisions - Provisions for pensions and other post-employment benefits (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
United Kingdom | Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.50%
Decrease in actuarial assumption		(0.50%)
United Kingdom | Actuarial assumption of expected rates of inflation
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.20%
Decrease in actuarial assumption		(0.05%)
United States | Actuarial assumption of discount rates
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.30%
Decrease in actuarial assumption		(0.50%)
Eurozone | Actuarial assumption of expected rates of inflation
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.25%
Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on benefit obligations	€ 352	€ (454)	€ (963)
Plan assets | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on plan assets	€ (24)	€ 308	€ 696

Off Balance Sheet Commitments (

Off Balance Sheet Commitments (Details) - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2021	Apr. 09, 2021	Apr. 08, 2021
Kymab
Disclosure Of Off Balance Sheet Commitments [Line Items]
Commitments related to potential milestone payments for projects under collaboration agreements			$ 350
Tidal Therapeutics
Disclosure Of Off Balance Sheet Commitments [Line Items]
Commitments related to potential milestone payments for projects under collaboration agreements		$ 310
Biond Biologics
Disclosure Of Off Balance Sheet Commitments [Line Items]
Upfront payment	$ 125
Commitments related to potential milestone payments for projects under collaboration agreements	$ 1,000

Litigation and Arbitration Pr_2

Litigation and Arbitration Proceedings (Details) - Action for which we are defendant	1 Months Ended		6 Months Ended
	Feb. 28, 2021USD ($)	Jul. 31, 2020lawsuit	Jun. 30, 2021injury_caseplaintiff	May 17, 2021manufacturer
Zantac litigation in the US | Product liabilities
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number of cases | injury_case			1,501
Number of plaintiffs | plaintiff			2,878
Zantac litigation in the US | Product liabilities | Federal MDL Court
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number of cases | injury_case			1,321
Number of plaintiffs | plaintiff			1,753
Zantac litigation in the US | Product liabilities | California State Court
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number of cases | injury_case			54
Number of plaintiffs | plaintiff			1,063
Depakine product litigation in France | Product liabilities
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number of administrative proceedings | lawsuit		3
Plavix related litigation in Hawaii
Disclosure of Legal and Arbitral Proceedings [Line Items]
Penalty fee incurred | $	$ 417,006,000
Plavix related litigation in Hawaii | Sanofi and Bristol Myers Squibb (BMS)
Disclosure of Legal and Arbitral Proceedings [Line Items]
Total amount of penalties fee incurred | $	$ 834,012,000
340-B drug pricing program in the United States
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number of other manufacturers which received a similar letter from HRSA | manufacturer				5

Other Operating Income And Ex_3

Other Operating Income And Expenses - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 409	€ 281	€ 696
Other operating expense	709	693	1,415
Other operating income (expense) | Regeneron
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	88	79	€ 164
Other related parties | Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	100	92
Gains on divestment of some mature products	156	€ 147
Daiichi Sankyo | Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 119

Other Operating Income And Ex_4

Other Operating Income And Expenses - Other Income and Expense (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	€ (709)	€ (693)	€ (1,415)
Other operating income	409	281	696
Other operating income/(expenses), net related to Regeneron Alliance	(555)	(446)	(926)
Monoclonal Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(586)	(482)	(1,001)
Immuno-Oncology Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	37	44	89
Other (mainly Zaltrap®)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(6)	(8)	(14)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance | Monoclonal Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(521)	(341)	(727)
Additional share of profit paid by Regeneron towards development costs | Monoclonal Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	51	35	75
Reimbursement to Regeneron of selling expenses incurred | Monoclonal Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(116)	(176)	(349)
Other operating income (expense) | Other related parties
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	100	92
Regeneron | Reimbursement to Regeneron of selling expenses incurred | Other related parties
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(643)	(525)
Regeneron | Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 88	€ 79	€ 164

Restructuring Costs and Simil_3

Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Analysis of income and expense [abstract]
Employee-related expenses	€ 72	€ 642	€ 690
Charges, gains or losses on assets	65	62	149
Compensation for early termination of contracts (other than contracts of employment)	10	11	40
Decontamination costs	0	0	(2)
Other restructuring costs	180	43	187
Total	€ 327	€ 758	€ 1,064

Restructuring Costs and Simil_4

Restructuring Costs and Similar Items - Additional Information (Details) € in Millions	12 Months Ended
	Jun. 30, 2021EUR (€)
Analysis of income and expense [abstract]
Decrease of total expense of restructuring activities	€ 431

Other Gains and Losses, and L_2

Other Gains and Losses, and Litigation (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Analysis of income and expense [abstract]
Other gains and litigation	€ 0	€ 136	€ 136

Financial Expenses and Income -

Financial Expenses and Income - Summary of Analysis of Financial Income and Expenses (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of detailed information about finance income expense [Line Items]
Cost of debt	€ (168)	€ (166)	€ (328)
Interest income	30	66	103
Cost of net debt	(138)	(100)	(225)
Non-operating foreign exchange gains/(losses)	4	2	(6)
Unwinding of discounting of provisions	(5)	(6)	(11)
Net interest cost related to employee benefits	(23)	(32)	(59)
Gains/(losses) on disposals of financial assets	3	0	6
Net interest expense on lease liabilities	(15)	(19)	(38)
Other	13	(12)	(4)
Net financial income/(expenses)	(161)	(167)	(337)
Financial expenses	(189)	(198)	(390)
Financial income	28	31	53
Interest rate and currency derivatives used to hedge debt
Disclosure of detailed information about finance income expense [Line Items]
Gain on derivatives used to manage debt	5	58	93
Gain on derivatives used to manage cash and cash equivalents	€ 28	€ 37	€ 66

Income Tax Expense - Summary of

Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Taxes [Abstract]
Current taxes	€ (806)	€ (1,127)	€ (1,912)
Deferred taxes	124	133	99
Total	(682)	(994)	(1,813)
Income before tax and investments accounted for using the equity method	€ 3,452	€ 9,941	€ 13,804

Income Tax Expense - Summary _2

Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Taxes [Abstract]
Standard tax rate applicable in France	28.40%	32.00%	32.00%
Difference between the standard French tax rate and the rates applicable to Sanofi	(10.10%)	(20.20%)	(18.20%)
Revisions to tax exposures and settlements of tax disputes	1.00%	0.20%	0.50%
Fair value remeasurement of contingent consideration liabilities	0.20%	(0.10%)	0.00%
Other	0.30%	(1.90%)	(1.20%)
Effective tax rate	19.80%	10.00%	13.10%

Segment Information - Additiona

Segment Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021segment
Operating Segments [Abstract]
Number of operating segments	3

Segment Information - Summary o

Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of geographical areas [line items]
Net sales	€ 17,335	€ 17,180	€ 36,041
Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	13,196	13,020	25,674
Pharmaceuticals | General Medicines
Disclosure of geographical areas [line items]
Net sales	7,218	7,618
Pharmaceuticals | Lantus
Disclosure of geographical areas [line items]
Net sales	1,289	1,417
Pharmaceuticals | Toujeo
Disclosure of geographical areas [line items]
Net sales	500	496
Pharmaceuticals | Praluent
Disclosure of geographical areas [line items]
Net sales	104	146
Pharmaceuticals | Multaq
Disclosure of geographical areas [line items]
Net sales	151	154
Pharmaceuticals | Lovenox
Disclosure of geographical areas [line items]
Net sales	768	630
Pharmaceuticals | Plavix
Disclosure of geographical areas [line items]
Net sales	485	508
Pharmaceuticals | Generics
Disclosure of geographical areas [line items]
Net sales	394	421
Pharmaceuticals | Specialty Care
Disclosure of geographical areas [line items]
Net sales	5,978	5,402
Pharmaceuticals | Aubagio
Disclosure of geographical areas [line items]
Net sales	994	1,068
Pharmaceuticals | Cerezyme
Disclosure of geographical areas [line items]
Net sales	343	368
Pharmaceuticals | Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	483	472
Pharmaceuticals | Fabrazyme
Disclosure of geographical areas [line items]
Net sales	412	413
Pharmaceuticals | Eloctate
Disclosure of geographical areas [line items]
Net sales	278	330
Pharmaceuticals | Jevtana
Disclosure of geographical areas [line items]
Net sales	240	271
Pharmaceuticals | Dupixent
Disclosure of geographical areas [line items]
Net sales	2,290	1,634
Vaccines
Disclosure of geographical areas [line items]
Net sales	1,937	1,836	5,973
Vaccines | Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	1,053	1,059
Vaccines | Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	196	179
Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	2,202	2,324	4,394
Consumer Healthcare | Allergy
Disclosure of geographical areas [line items]
Net sales	343	381
Consumer Healthcare | Pain Care
Disclosure of geographical areas [line items]
Net sales	528	549
Consumer Healthcare | Digestive Wellness
Disclosure of geographical areas [line items]
Net sales	573	491
Europe
Disclosure of geographical areas [line items]
Net sales	4,472	4,345
Europe | Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	3,575	3,347
Europe | Pharmaceuticals | General Medicines
Disclosure of geographical areas [line items]
Net sales	2,228	2,232
Europe | Pharmaceuticals | Lantus
Disclosure of geographical areas [line items]
Net sales	246	281
Europe | Pharmaceuticals | Toujeo
Disclosure of geographical areas [line items]
Net sales	195	188
Europe | Pharmaceuticals | Praluent
Disclosure of geographical areas [line items]
Net sales	75	56
Europe | Pharmaceuticals | Multaq
Disclosure of geographical areas [line items]
Net sales	12	12
Europe | Pharmaceuticals | Lovenox
Disclosure of geographical areas [line items]
Net sales	368	298
Europe | Pharmaceuticals | Plavix
Disclosure of geographical areas [line items]
Net sales	60	66
Europe | Pharmaceuticals | Generics
Disclosure of geographical areas [line items]
Net sales	4	5
Europe | Pharmaceuticals | Specialty Care
Disclosure of geographical areas [line items]
Net sales	1,347	1,115
Europe | Pharmaceuticals | Aubagio
Disclosure of geographical areas [line items]
Net sales	264	231
Europe | Pharmaceuticals | Cerezyme
Disclosure of geographical areas [line items]
Net sales	124	125
Europe | Pharmaceuticals | Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	200	193
Europe | Pharmaceuticals | Fabrazyme
Disclosure of geographical areas [line items]
Net sales	111	98
Europe | Pharmaceuticals | Eloctate
Disclosure of geographical areas [line items]
Net sales	0	0
Europe | Pharmaceuticals | Jevtana
Disclosure of geographical areas [line items]
Net sales	75	92
Europe | Pharmaceuticals | Dupixent
Disclosure of geographical areas [line items]
Net sales	289	174
Europe | Vaccines
Disclosure of geographical areas [line items]
Net sales	244	281
Europe | Vaccines | Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	145	162
Europe | Vaccines | Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	18	5
Europe | Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	653	717
Europe | Consumer Healthcare | Allergy
Disclosure of geographical areas [line items]
Net sales	34	36
Europe | Consumer Healthcare | Pain Care
Disclosure of geographical areas [line items]
Net sales	250	244
Europe | Consumer Healthcare | Digestive Wellness
Disclosure of geographical areas [line items]
Net sales	200	192
United States
Disclosure of geographical areas [line items]
Net sales	6,088	5,880	€ 13,465
United States | Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	4,892	4,806
United States | Pharmaceuticals | General Medicines
Disclosure of geographical areas [line items]
Net sales	1,262	1,458
United States | Pharmaceuticals | Lantus
Disclosure of geographical areas [line items]
Net sales	429	474
United States | Pharmaceuticals | Toujeo
Disclosure of geographical areas [line items]
Net sales	120	143
United States | Pharmaceuticals | Praluent
Disclosure of geographical areas [line items]
Net sales	5	68
United States | Pharmaceuticals | Multaq
Disclosure of geographical areas [line items]
Net sales	132	135
United States | Pharmaceuticals | Lovenox
Disclosure of geographical areas [line items]
Net sales	15	15
United States | Pharmaceuticals | Plavix
Disclosure of geographical areas [line items]
Net sales	5	4
United States | Pharmaceuticals | Generics
Disclosure of geographical areas [line items]
Net sales	70	75
United States | Pharmaceuticals | Specialty Care
Disclosure of geographical areas [line items]
Net sales	3,630	3,348
United States | Pharmaceuticals | Aubagio
Disclosure of geographical areas [line items]
Net sales	666	775
United States | Pharmaceuticals | Cerezyme
Disclosure of geographical areas [line items]
Net sales	83	90
United States | Pharmaceuticals | Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	180	178
United States | Pharmaceuticals | Fabrazyme
Disclosure of geographical areas [line items]
Net sales	190	206
United States | Pharmaceuticals | Eloctate
Disclosure of geographical areas [line items]
Net sales	216	234
United States | Pharmaceuticals | Jevtana
Disclosure of geographical areas [line items]
Net sales	119	123
United States | Pharmaceuticals | Dupixent
Disclosure of geographical areas [line items]
Net sales	1,740	1,310
United States | Vaccines
Disclosure of geographical areas [line items]
Net sales	626	491
United States | Vaccines | Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	241	183
United States | Vaccines | Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	0	13
United States | Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	570	583
United States | Consumer Healthcare | Allergy
Disclosure of geographical areas [line items]
Net sales	200	214
United States | Consumer Healthcare | Pain Care
Disclosure of geographical areas [line items]
Net sales	91	98
United States | Consumer Healthcare | Digestive Wellness
Disclosure of geographical areas [line items]
Net sales	61	36
Other countries
Disclosure of geographical areas [line items]
Net sales	6,775	6,955
Other countries | Pharmaceuticals
Disclosure of geographical areas [line items]
Net sales	4,729	4,867
Other countries | Pharmaceuticals | General Medicines
Disclosure of geographical areas [line items]
Net sales	3,728	3,928
Other countries | Pharmaceuticals | Lantus
Disclosure of geographical areas [line items]
Net sales	614	662
Other countries | Pharmaceuticals | Toujeo
Disclosure of geographical areas [line items]
Net sales	185	165
Other countries | Pharmaceuticals | Praluent
Disclosure of geographical areas [line items]
Net sales	24	22
Other countries | Pharmaceuticals | Multaq
Disclosure of geographical areas [line items]
Net sales	7	7
Other countries | Pharmaceuticals | Lovenox
Disclosure of geographical areas [line items]
Net sales	385	317
Other countries | Pharmaceuticals | Plavix
Disclosure of geographical areas [line items]
Net sales	420	438
Other countries | Pharmaceuticals | Generics
Disclosure of geographical areas [line items]
Net sales	320	341
Other countries | Pharmaceuticals | Specialty Care
Disclosure of geographical areas [line items]
Net sales	1,001	939
Other countries | Pharmaceuticals | Aubagio
Disclosure of geographical areas [line items]
Net sales	64	62
Other countries | Pharmaceuticals | Cerezyme
Disclosure of geographical areas [line items]
Net sales	136	153
Other countries | Pharmaceuticals | Myozyme/Lumizyme
Disclosure of geographical areas [line items]
Net sales	103	101
Other countries | Pharmaceuticals | Fabrazyme
Disclosure of geographical areas [line items]
Net sales	111	109
Other countries | Pharmaceuticals | Eloctate
Disclosure of geographical areas [line items]
Net sales	62	96
Other countries | Pharmaceuticals | Jevtana
Disclosure of geographical areas [line items]
Net sales	46	56
Other countries | Pharmaceuticals | Dupixent
Disclosure of geographical areas [line items]
Net sales	261	150
Other countries | Vaccines
Disclosure of geographical areas [line items]
Net sales	1,067	1,064
Other countries | Vaccines | Polio/Pertussis/Hib vaccines
Disclosure of geographical areas [line items]
Net sales	667	714
Other countries | Vaccines | Influenza vaccines
Disclosure of geographical areas [line items]
Net sales	178	161
Other countries | Consumer Healthcare
Disclosure of geographical areas [line items]
Net sales	979	1,024
Other countries | Consumer Healthcare | Allergy
Disclosure of geographical areas [line items]
Net sales	109	131
Other countries | Consumer Healthcare | Pain Care
Disclosure of geographical areas [line items]
Net sales	187	207
Other countries | Consumer Healthcare | Digestive Wellness
Disclosure of geographical areas [line items]
Net sales	€ 312	€ 263

Segment Information - Segment R

Segment Information - Segment Results (Details)	May 29, 2020shares
Regeneron
Disclosure of operating segments [Line Items]
Non-current financial assets, number of shares (in shares)	400,000

Segment Information - Schedule

Segment Information - Schedule of Segment Results (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of operating segments [Line Items]
Net sales	€ 17,335	€ 17,180	€ 36,041
Other revenues	596	574	1,328
Cost of sales	(5,541)	(5,543)	(12,157)
Research and development expenses	(2,663)	(2,692)	(5,529)
Selling and general expenses	(4,530)	(4,607)	(9,390)
Net income attributable to non-controlling interests	20	20	36
Total
Disclosure of operating segments [Line Items]
Net sales	17,335	17,180	36,041
Other revenues	596	574	1,328
Cost of sales	(5,541)	(5,507)	(12,104)
Research and development expenses	(2,663)	(2,692)	(5,529)
Selling and general expenses	(4,530)	(4,607)	(9,390)
Other operating income and expenses	(300)	(255)	(562)
Share of profit (loss) from investments accounted for using equity method	26	11	16
Net income attributable to non-controlling interests	(20)	(21)	(38)
Business operating income	4,903	4,683	9,762
Pharmaceuticals
Disclosure of operating segments [Line Items]
Net sales	13,196	13,020	25,674
Other revenues	108	70	128
Cost of sales	(3,403)	(3,406)	(6,980)
Research and development expenses	(2,041)	(2,065)	(4,170)
Selling and general expenses	(2,480)	(2,388)	(4,926)
Other operating income and expenses	(466)	(150)	(490)
Share of profit (loss) from investments accounted for using equity method	13	4	5
Net income attributable to non-controlling interests	(16)	(17)	(33)
Business operating income	4,911	5,068	9,208
Vaccines
Disclosure of operating segments [Line Items]
Net sales	1,937	1,836	5,973
Other revenues	461	474	1,141
Cost of sales	(1,254)	(1,176)	(3,312)
Research and development expenses	(316)	(319)	(682)
Selling and general expenses	(359)	(369)	(789)
Other operating income and expenses	121	4	4
Share of profit (loss) from investments accounted for using equity method	8	0	2
Net income attributable to non-controlling interests	0	0	0
Business operating income	598	450	2,337
Consumer Healthcare
Disclosure of operating segments [Line Items]
Net sales	2,202	2,324	4,394
Other revenues	27	30	59
Cost of sales	(753)	(781)	(1,528)
Research and development expenses	(69)	(69)	(153)
Selling and general expenses	(700)	(744)	(1,419)
Other operating income and expenses	23	21	53
Share of profit (loss) from investments accounted for using equity method	5	7	9
Net income attributable to non-controlling interests	(4)	(4)	(5)
Business operating income	731	784	1,410
Other
Disclosure of operating segments [Line Items]
Net sales	0	0	0
Other revenues	0	0	0
Cost of sales	(131)	(144)	(284)
Research and development expenses	(237)	(239)	(524)
Selling and general expenses	(991)	(1,106)	(2,256)
Other operating income and expenses	22	(130)	(129)
Share of profit (loss) from investments accounted for using equity method	0	0	0
Net income attributable to non-controlling interests	0	0	0
Business operating income	€ (1,337)	€ (1,619)	€ (3,193)

Segment Information - Schedul_2

Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (€) € in Millions	May 29, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of operating segments [Line Items]
Net income attributable to non-controlling interests		€ 20	€ 20	€ 36
Fair value remeasurement of contingent consideration		(4)	54	124
Restructuring costs and similar items		(327)	(758)	(1,064)
Other gains and losses, and litigation		0	136	136
Operating income		3,613	10,108	14,141
Financial expenses		(189)	(198)	(390)
Financial income		28	31	53
Income before tax and investments accounted for using the equity method		3,452	9,941	13,804
Regeneron
Disclosure of operating segments [Line Items]
Non-current financial assets, number of shares (in shares)	400,000
Regeneron | Public Offering
Disclosure of operating segments [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	13,000,000
Regeneron | Repurchase from the counterpart | Regeneron Pharmaceuticals, Inc
Disclosure of operating segments [Line Items]
Number of shares issued in transaction (in shares)	9,800,000
Operating segments
Disclosure of operating segments [Line Items]
Business operating income		4,903	4,683	9,762
Material reconciling items
Disclosure of operating segments [Line Items]
Share of profit (loss) from investments accounted for using equity method		(26)	(11)	(16)
Net income attributable to non-controlling interests		20	21	38
Amortization and impairment of intangible assets		(953)	(1,206)	(2,011)
Fair value remeasurement of contingent consideration		(4)	54	124
Expenses arising from the impact of acquisitions on inventories		0	(36)	(53)
Restructuring costs and similar items		(327)	(758)	(1,064)
Other gains and losses, and litigation		0	136	136
Gain on divestment of Regeneron shares on May 29, 2020		€ 0	€ 7,225	€ 7,225

Segment Information - Schedul_3

Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Total
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	€ 214	€ 196	€ 201
Acquisitions of property, plant and equipment	668	502	1,254
Acquisitions of other intangible assets	350	180	860
Pharmaceuticals
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	144	149	154
Acquisitions of property, plant and equipment	445	294	755
Acquisitions of other intangible assets	263	153	532
Consumer Healthcare
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	70	44	47
Acquisitions of property, plant and equipment	196	181	404
Acquisitions of other intangible assets	81	21	322
Vaccines
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	0	3	0
Acquisitions of property, plant and equipment	27	27	95
Acquisitions of other intangible assets	€ 6	€ 6	€ 6

Segment Information - Summary_2

Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of geographical areas [line items]
Net sales	€ 17,335	€ 17,180	€ 36,041
Property, plant and equipment owned	9,503		9,365
Goodwill	44,979		44,364
Other intangible assets	19,466		18,421
Reportable geographical zones
Disclosure of geographical areas [line items]
Net sales	17,335	17,180	36,041
Property, plant and equipment owned	9,503	9,368	9,365
Goodwill	44,979	45,254	44,364
Other intangible assets	19,466	17,021	18,421
Europe
Disclosure of geographical areas [line items]
Net sales	4,472	4,345	9,151
Property, plant and equipment owned	5,874	5,683	5,895
Goodwill	0	0	0
Other intangible assets	7,272	6,544	6,278
France
Disclosure of geographical areas [line items]
Net sales	1,087	1,061	2,223
Property, plant and equipment owned	3,162	3,067	3,189
Goodwill	0	0	0
Other intangible assets	0	0	0
North America
Disclosure of geographical areas [line items]
Net sales	6,388	6,151	14,060
Property, plant and equipment owned	2,699	2,756	2,542
Goodwill	0	0	0
Other intangible assets	10,895	8,838	10,675
United States
Disclosure of geographical areas [line items]
Net sales	6,088	5,880	13,465
Property, plant and equipment owned	1,996	2,153	1,899
Goodwill	0	0	0
Other intangible assets	0	0	0
Other countries
Disclosure of geographical areas [line items]
Net sales	6,475	6,684	12,830
Property, plant and equipment owned	930	929	928
Goodwill	0	0	0
Other intangible assets	€ 1,299	€ 1,639	€ 1,468

Segment Information - Principal

Segment Information - Principal Customers and Credit Risk (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Customer one
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	11.00%	9.00%
Customer two
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	8.00%	6.00%
Customer three
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	5.00%	5.00%
Certain wholesalers in the United States
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	24.00%